BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. [PMID: 15269313 DOI: 10.1056/nejmoa033025] [Cited by in Crossref: 3602] [Cited by in F6Publishing: 1193] [Article Influence: 211.9] [Reference Citation Analysis]
Number Citing Articles
1 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, Moyer AN, Bolch E, Webb R, Haley S, Hatch AJ, Altomare IP, Sherrill GB, Chang DZ, Wells JL, Hsu SD, Jia J, Zafar SY, Nixon AB, Hurwitz HI. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. Oncologist 2021;26:465-e917. [PMID: 33469991 DOI: 10.1002/onco.13678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369-383. [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
4 Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 2012;106:748-55. [PMID: 22240781 DOI: 10.1038/bjc.2011.587] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
5 Rodrigues D, Longatto-Filho A, Martins SF. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. Biomed Res Int 2016;2016:6896024. [PMID: 27563673 DOI: 10.1155/2016/6896024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hu T, Li Z, Gao CY, Cho CH. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 2016;22:6876-6889. [PMID: 27570424 DOI: 10.3748/wjg.vss.i30.6876] [Reference Citation Analysis]
7 Aljubran A, Elshenawy MA, Kandil M, Zahir MN, Shaheen A, Gad A, Alshaer O, Alzahrani A, Eldali A, Bazarbashi S. Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study. Clin Med Insights Oncol 2019;13:1179554918825447. [PMID: 30728734 DOI: 10.1177/1179554918825447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
8 Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med 2013;10:192-205. [PMID: 24349829 DOI: 10.7497/j.issn.2095-3941.2013.04.003] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
9 De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A. Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes. Oncoimmunology 2016;5:e1127493. [PMID: 27467939 DOI: 10.1080/2162402X.2015.1127493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
10 Barzi A, Yang D, Mostofizadeh S, Lenz HJ. Trends in colorectal cancer mortality in hispanics: a SEER analysis. Oncotarget. 2017;8:108771-108777. [PMID: 29312566 DOI: 10.18632/oncotarget.21938] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Goodwin RA, Asmis TR. Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg. 2009;22:251-256. [PMID: 21037816 DOI: 10.1055/s-0029-1242465] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
12 Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-499. [PMID: 19536109 DOI: 10.1038/nrc2645] [Cited by in Crossref: 462] [Cited by in F6Publishing: 410] [Article Influence: 38.5] [Reference Citation Analysis]
13 Aghagolzadeh P, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 2016;22:5678-5693. [PMID: 27433083 DOI: 10.3748/wjg.v22.i25.5678] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
14 Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, Yang TS. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget 2016;7:22257-70. [PMID: 26989027 DOI: 10.18632/oncotarget.8076] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
15 Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther 2009;16:412-20. [PMID: 19955859 DOI: 10.1097/MJT.0b013e3181907ed9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
16 Hung CS, Wang YC, Guo JW, Yang RN, Lee CL, Shen MH, Huang CC, Huang CJ, Yang JY, Liu CY. Expression pattern of placenta specific 8 and keratin 20 in different types of gastrointestinal cancer. Mol Med Rep 2020;21:659-66. [PMID: 31974611 DOI: 10.3892/mmr.2019.10871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304. [PMID: 21208844 DOI: 10.3816/CCC.2010.n.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
18 Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG, Cancelliere C, Di Fiore PP, Bardelli A, Penna G, Rescigno M. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med 2016;22:624-31. [PMID: 27135741 DOI: 10.1038/nm.4078] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 23.8] [Reference Citation Analysis]
19 Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 2011;178:537-47. [PMID: 21281787 DOI: 10.1016/j.ajpath.2010.10.020] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 9.1] [Reference Citation Analysis]
20 Boeckx C, Van den Bossche J, De Pauw I, Peeters M, Lardon F, Baay M, Wouters A. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. BMC Res Notes 2015;8:203. [PMID: 26032726 DOI: 10.1186/s13104-015-1197-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
21 Jutten B, Rouschop KM. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle. 2014;13:42-51. [PMID: 24335351 DOI: 10.4161/cc.27518] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
22 Lu Y, Sandoval A, Voss S, Lai Z, Kneitz S, Boswell W, Boswell M, Savage M, Walter C, Warren W, Schartl M, Walter R. Oncogenic allelic interaction in Xiphophorus highlights hybrid incompatibility. Proc Natl Acad Sci U S A 2020;117:29786-94. [PMID: 33168740 DOI: 10.1073/pnas.2010133117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
23 Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12:600-7. [PMID: 16428506 DOI: 10.1158/1078-0432.CCR-05-1325] [Cited by in Crossref: 63] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
24 Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011;105:1646-53. [PMID: 22027708 DOI: 10.1038/bjc.2011.438] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
25 Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016;7:13665. [PMID: 27929064 DOI: 10.1038/ncomms13665] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 20.0] [Reference Citation Analysis]
26 Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 2010;9:3351-62. [PMID: 20923857 DOI: 10.1158/1535-7163.MCT-10-0376] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
27 Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Biagetti S, Alfonsi S, Giustini L, Loretelli C, Faloppi L, Bittoni A. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med. 2012;10:71. [PMID: 22490361 DOI: 10.1186/1479-5876-10-71] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
28 Cui D, Cao D, Yang Y, Qiu M, Huang Y, Yi C. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep 2014;41:1291-8. [PMID: 24390240 DOI: 10.1007/s11033-013-2974-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
29 Shan Z, Luo D, Liu Q, Cai S, Wang R, Ma Y, Li X. Proteomic profiling reveals a signature for optimizing prognostic prediction in Colon Cancer. J Cancer 2021;12:2199-205. [PMID: 33758598 DOI: 10.7150/jca.50630] [Reference Citation Analysis]
30 Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7:493-507. [PMID: 20551942 DOI: 10.1038/nrclinonc.2010.97] [Cited by in Crossref: 448] [Cited by in F6Publishing: 397] [Article Influence: 40.7] [Reference Citation Analysis]
31 Hutchinson RA, Adams RA, McArt DG, Salto-Tellez M, Jasani B, Hamilton PW. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med 2015;13:217. [PMID: 26149458 DOI: 10.1186/s12967-015-0531-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
32 Ibrahim EM, Zekri JM, Bin Sadiq BM. Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis. 2010;25:713-721. [PMID: 20309588 DOI: 10.1007/s00384-010-0927-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
33 Wan ML, Wang Y, Zeng Z, Deng B, Zhu BS, Cao T, Li YK, Xiao J, Han Q, Wu Q. Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways. Biosci Rep. 2020;40. [PMID: 32149326 DOI: 10.1042/bsr20200265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
34 Sato K, Shin MS, Sakimura A, Zhou Y, Tanaka T, Kawanishi M, Kawasaki Y, Yokoyama S, Koizumi K, Saiki I, Sakurai H. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Cancer Sci 2013;104:1315-22. [PMID: 23822636 DOI: 10.1111/cas.12225] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
35 Engelmann BE, Loft A, Kjær A, Nielsen HJ, Gerds TA, Benzon EV, Brünner N, Christensen IJ, Hansson SH, Holländer NH, Kristensen MH, Löfgren J, Markova E, Sloth C, Højgaard L. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist 2014;19:164-72. [PMID: 24451199 DOI: 10.1634/theoncologist.2013-0229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Guo Y, Parry JJ, Laforest R, Rogers BE, Anderson CJ. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med 2013;54:1621-9. [PMID: 23873478 DOI: 10.2967/jnumed.112.118539] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
37 Segelov E, Chan D, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Pavlakis N. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer. 2014;111:1122-1131. [PMID: 25072258 DOI: 10.1038/bjc.2014.404] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
38 Chen W, Shen B, Sun X. Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules. Mol Imaging 2019;18:1536012118823473. [PMID: 30799684 DOI: 10.1177/1536012118823473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
39 Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR. Episensitization: Defying Time's Arrow. Front Oncol 2015;5:134. [PMID: 26125013 DOI: 10.3389/fonc.2015.00134] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
40 Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. Int J Nanomedicine 2020;15:5719-43. [PMID: 32821098 DOI: 10.2147/IJN.S254774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
41 Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007;13:5867-76. [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
42 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 174] [Article Influence: 40.6] [Reference Citation Analysis]
43 Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, Gorgoulis V, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78. [PMID: 21441573 DOI: 10.1634/theoncologist.2010-0429] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
44 Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014;32:113-122. [PMID: 23568716 DOI: 10.1007/s10637-013-9956-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
45 Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer. 2010;102:162-164. [PMID: 19953097 DOI: 10.1038/sj.bjc.6605471] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.7] [Reference Citation Analysis]
46 Tanaka T, Kaida T, Yokoi K, Ishii S, Nishizawa N, Kawamata H, Katoh H, Sato T, Nakamura T, Watanabe M, Yamashita K. Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer. Oncol Lett 2019;17:1257-66. [PMID: 30655893 DOI: 10.3892/ol.2018.9728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
47 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
48 Tian X, Zhou JG, Zeng Z, Shuai T, Yi LJ, Ma L, Wang Y, Cao H, Song GM. Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. Med Oncol 2015;32:127. [PMID: 25794489 DOI: 10.1007/s12032-015-0521-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
49 Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-8. [PMID: 19564563 DOI: 10.1093/jnci/djp177] [Cited by in Crossref: 261] [Cited by in F6Publishing: 191] [Article Influence: 21.8] [Reference Citation Analysis]
50 Kye BH, Cho HM. Overview of radiation therapy for treating rectal cancer. Ann Coloproctol 2014;30:165-74. [PMID: 25210685 DOI: 10.3393/ac.2014.30.4.165] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
51 Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol. 2008;14:5403-5411. [PMID: 18803351 DOI: 10.3748/wjg.14.5403] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
52 Zhu K, Yan H, Wang R, Zhu H, Meng X, Xu X, Dou X, Chen D. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.Med Oncol. 2014;31:16. [PMID: 24861917 DOI: 10.1007/s12032-014-0016-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
53 Loong HH, Ma BB, Chan AT. Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol 2009;2009:967920. [PMID: 19365583 DOI: 10.1155/2009/967920] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
54 Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009;100:1330-1335. [PMID: 19367287 DOI: 10.1038/sj.bjc.6605008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
55 Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, Kim MK, Sym SJ, Lee JS, Kang YK. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci 2007;22 Suppl:S98-S103. [PMID: 17923763 DOI: 10.3346/jkms.2007.22.S.S98] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Gattenlöhner S, Etschmann B, Kunzmann V, Thalheimer A, Hack M, Kleber G, Einsele H, Germer C, Müller-Hermelink HK. Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy. J Oncol 2009;2009:831626. [PMID: 20300583 DOI: 10.1155/2009/831626] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
57 Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 2014;8:1084-94. [PMID: 24913799 DOI: 10.1016/j.molonc.2014.05.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 11.3] [Reference Citation Analysis]
58 Peled N, Yoshida K, Wynes MW, Hirsch FR. Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Ther Adv Med Oncol 2009;1:137-44. [PMID: 21789118 DOI: 10.1177/1758834009347923] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
59 Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs 2012;30:1660-70. [PMID: 21796439 DOI: 10.1007/s10637-011-9724-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
60 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 240] [Article Influence: 141.0] [Reference Citation Analysis]
61 Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? Oncotarget. 2017;8:100863-100898. [PMID: 29246028 DOI: 10.18632/oncotarget.19809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-14. [PMID: 20551945 DOI: 10.1038/nrclinonc.2010.64] [Cited by in Crossref: 174] [Cited by in F6Publishing: 151] [Article Influence: 15.8] [Reference Citation Analysis]
63 Cidón EU. The challenge of metastatic colorectal cancer. Clin Med Insights Oncol 2010;4:55-60. [PMID: 20711244 DOI: 10.4137/cmo.s5214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Cercek A, Saltz L. BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients. Curr Treat Options Oncol 2011;12:126-35. [PMID: 21472513 DOI: 10.1007/s11864-011-0147-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
65 Pranchevicius MC, Vieira TR. Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Bioengineered 2013;4:305-12. [PMID: 23644447 DOI: 10.4161/bioe.24666] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
66 Modest DP, Hiddemann W, Heinemann V. [Chemotherapy of metastatic colorectal cancer]. Internist (Berl) 2014;55:37-42. [PMID: 24399471 DOI: 10.1007/s00108-013-3314-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
67 Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008;66:6-19. [PMID: 18503606 DOI: 10.1111/j.1365-2125.2008.03187.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
68 Paller CJ, Huang EP, Luechtefeld T, Massett HA, Williams CC, Zhao J, Gravell AE, Tamashiro T, Reeves SA, Rosner GL, Carducci MA, Rubinstein L, Ivy SP. Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials. Front Med (Lausanne) 2019;6:122. [PMID: 31214592 DOI: 10.3389/fmed.2019.00122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Yokoyama T, Tam J, Kuroda S, Scott AW, Aaron J, Larson T, Shanker M, Correa AM, Kondo S, Roth JA, Sokolov K, Ramesh R. EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS One 2011;6:e25507. [PMID: 22087216 DOI: 10.1371/journal.pone.0025507] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
70 Fairchild AH, White SB. Decision Making in Interventional Oncology: Intra-arterial Therapies for Metastatic Colorectal Cancer-Y90 and Chemoembolization. Semin Intervent Radiol 2017;34:87-91. [PMID: 28579675 DOI: 10.1055/s-0037-1601854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K, Yuan Y. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther 2019;20:391-6. [PMID: 30307354 DOI: 10.1080/15384047.2018.1529120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Yang Q, Huang Y, Jiang Z, Wang H, Li W, Zhang B, Xie D. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer. Onco Targets Ther 2018;11:2467-73. [PMID: 29760556 DOI: 10.2147/OTT.S154220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Yoshida Y, Hoshino S, Miyake T, Fukuda S, Yamada K, Naoya A, Tanimura S, Yamashita Y. Early start of chemotherapy after resection of brain metastasis from colon cancer with synchronous multiple liver metastases. Case Rep Oncol 2012;5:290-5. [PMID: 22740818 DOI: 10.1159/000339614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
74 Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget 2017;8:7666-77. [PMID: 28032593 DOI: 10.18632/oncotarget.13835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
75 Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057-1077. [PMID: 17530336 DOI: 10.1007/s11605-006-0061-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 127] [Article Influence: 10.8] [Reference Citation Analysis]
76 Zhuang HQ, Wang J, Yuan ZY, Zhao LJ, Wang P, Wang CL. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J Exp Clin Cancer Res 2009;28:123. [PMID: 19723324 DOI: 10.1186/1756-9966-28-123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
77 Chandrasekhar JL, Cox KM, Erickson LD. B Cell Responses in the Development of Mammalian Meat Allergy. Front Immunol 2020;11:1532. [PMID: 32765532 DOI: 10.3389/fimmu.2020.01532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, Dougherty B, Ducreux M, Soria JC, Friend S, Derry J, Laurent-Puig P. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. Clin Cancer Res 2014;20:265-72. [PMID: 24170544 DOI: 10.1158/1078-0432.CCR-13-1943] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
79 Sun Y, Luo M, Chang G, Ren W, Wu K, Li X, Shen J, Zhao X, Hu Y. Phosphorylation of Ser6 in hnRNPA1 by S6K2 regulates glucose metabolism and cell growth in colorectal cancer. Oncol Lett 2017;14:7323-31. [PMID: 29344170 DOI: 10.3892/ol.2017.7085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
80 Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol. 2011;3:1-9. [PMID: 21267397 DOI: 10.4251/wjgo.v3.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
81 Desautels D, Harlos C, Czaykowski P. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog 2014;13:13. [PMID: 25525412 DOI: 10.4103/1477-3163.145609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
82 Wells SA Jr, Santoro M. Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab 2014;99:1543-55. [PMID: 24423326 DOI: 10.1210/jc.2013-2622] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
83 Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, Abbas R, Martins P, Zacharchuk C, Hidalgo M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res 2008;14:5602-9. [PMID: 18765554 DOI: 10.1158/1078-0432.CCR-08-0433] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
84 Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-84. [PMID: 21275455 DOI: 10.1007/BF03256395] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
85 Hashino S, Kobayashi S, Takahata M, Onozawa M, Nakagawa M, Kawamura T, Fujisawa F, Izumiyama K, Kahata K, Kondo T, Asaka M. Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer. Int J Clin Oncol 2008;13:176-80. [PMID: 18463966 DOI: 10.1007/s10147-007-0716-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol. 2013;19:4511-4519. [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
87 Graves-Deal R, Bogatcheva G, Rehman S, Lu Y, Higginbotham JN, Singh B. Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget 2019;10:1320-33. [PMID: 30863492 DOI: 10.18632/oncotarget.26663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
88 Jia J, Morse MA, Nagy RJ, Lanman RB, Strickler JH. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. Front Oncol 2018;8:305. [PMID: 30211110 DOI: 10.3389/fonc.2018.00305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
89 Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol 2020;13:1756284820917527. [PMID: 32536977 DOI: 10.1177/1756284820917527] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
90 Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432. [PMID: 20003271 DOI: 10.1186/1471-2407-9-432] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 8.7] [Reference Citation Analysis]
91 Dionísio de Sousa IJ, Ferreira J, Rodrigues J, Bonito N, Jacinto P, Marques M, Ribeiro J, Pais A, Gervásio H. Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. ESMO Open 2016;1:e000045. [PMID: 27843607 DOI: 10.1136/esmoopen-2016-000045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
92 Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother 2012;35:367-73. [PMID: 22576341 DOI: 10.1097/CJI.0b013e3182562d76] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
93 Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer. 2008;99:868-874. [PMID: 19238629 DOI: 10.1038/sj.bjc.6604622] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
94 Thomas VA, Balthasar JP. Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. AAPS J 2016;18:923-32. [PMID: 27029796 DOI: 10.1208/s12248-016-9909-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
95 Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008;99:1239-1245. [PMID: 18797458 DOI: 10.1038/sj.bjc.6604673] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
96 Kondo Y, Hayashi K, Kawakami K, Miwa Y, Hayashi H, Yamamoto M. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer. BMC Cancer 2017;17:311. [PMID: 28468669 DOI: 10.1186/s12885-017-3305-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
97 Formiga MN, Fanelli MF, Dettino AL, Nicolau UR, Cavicchioli M, Lima EN, de Mello CA. Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer? J Gastrointest Oncol 2016;7:365-72. [PMID: 27284468 DOI: 10.21037/jgo.2016.02.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
98 Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13:64-73. [PMID: 21227396 DOI: 10.1016/j.jmoldx.2010.11.005] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 9.6] [Reference Citation Analysis]
99 Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PLoS One. 2012;7:e50925. [PMID: 23226426 DOI: 10.1371/journal.pone.0050925] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
100 Dvorak J, Sitorova V, Ryska A, Sirak I, Richter I, Hatlova J, Ferko A, Melichar B, Petera J. [Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma]. Strahlenther Onkol 2012;188:833-8. [PMID: 22847519 DOI: 10.1007/s00066-012-0160-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
101 Mao C, Liao RY, Qiu LX, Wang XW, Ding H, Chen Q. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep. 2011;38:2219-2223. [PMID: 20857202 DOI: 10.1007/s11033-010-0351-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
102 Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131-8. [PMID: 16835584 DOI: 10.1038/sj.bjc.6603233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
103 Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett 2018;15:7497-505. [PMID: 29725456 DOI: 10.3892/ol.2018.8300] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
104 Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K. Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today 2009;39:27-31. [PMID: 19132464 DOI: 10.1007/s00595-008-3843-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
105 Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007;13:3806-3815. [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
106 Cleary JM, Calvo E, Moreno V, Juric D, Shapiro GI, Vanderwal CA, Hu B, Gifford M, Barch D, Roberts-Rapp L, Ansell PJ, Xiong H, Ocampo C, Tolcher AW. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs 2020;38:1483-94. [PMID: 32189093 DOI: 10.1007/s10637-020-00908-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
107 Viala M, Vinches M, Alexandre M, Mollevi C, Durigova A, Hayaoui N, Homicsko K, Cuenant A, Gongora C, Gianni L, Tosi D. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. Br J Cancer 2018;118:679-97. [PMID: 29438365 DOI: 10.1038/bjc.2017.473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
108 Hsiung PL, Wang T. In vivo biomarkers for targeting colorectal neoplasms. Cancer Biomark 2008;4:329-40. [PMID: 19126961 DOI: 10.3233/cbm-2008-4605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
109 Masuko K, Okazaki S, Satoh M, Tanaka G, Ikeda T, Torii R, Ueda E, Nakano T, Danbayashi M, Tsuruoka T. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One. 2012;7:e29728. [PMID: 22272243 DOI: 10.1371/journal.pone.0029728] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
110 Mehmood RK. Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncol Rev 2014;8:256. [PMID: 25992242 DOI: 10.4081/oncol.2014.256] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
111 Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007;67:2045-75. [PMID: 17883287 DOI: 10.2165/00003495-200767140-00006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
112 Dasari VR, Velpula KK, Alapati K, Gujrati M, Tsung AJ. Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. PLoS One 2012;7:e31884. [PMID: 22348136 DOI: 10.1371/journal.pone.0031884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
113 Giampieri R, Mandolesi A, Abouelkhair KM, Loretelli C, Del Prete M, Faloppi L, Maristella B, Ibrahim EM, Scarpelli M, Cascinu S, Scartozzi M. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med 2015;13:140. [PMID: 25943333 DOI: 10.1186/s12967-015-0501-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
114 Ibrahem S, Seth R, O'Sullivan B, Fadhil W, Taniere P, Ilyas M. Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection. Int J Exp Pathol 2010;91:500-5. [PMID: 21199003 DOI: 10.1111/j.1365-2613.2010.00733.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
115 Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1-9. [PMID: 19737224 DOI: 10.1111/j.1365-2249.2009.03992.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 163] [Article Influence: 16.6] [Reference Citation Analysis]
116 Kwak Y, Yun S, Nam SK, Seo AN, Lee KS, Shin E, Oh HK, Kim DW, Kang SB, Kim WH, Lee HS. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. J Transl Med 2017;15:167. [PMID: 28764718 DOI: 10.1186/s12967-017-1265-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
117 Modjtahedi H, Khelwatty SA, Kirk RS, Seddon AM, Essapen S, Del Vecchio CA, Wong AJ, Eccles S. Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. Br J Cancer 2012;106:883-8. [PMID: 22315050 DOI: 10.1038/bjc.2012.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
118 You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, Li CF, Zou X, Yu T, Cao JY, Zhang MX, Jiang R, Sun R, Mo HY, Guo L, Cao KJ, Lin AH, Sun Y, Qian CN, Ma J, Chen MY. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. Theranostics 2017;7:2314-24. [PMID: 28740554 DOI: 10.7150/thno.19710] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
119 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020;11:761-808. [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
120 Boeckx N, Peeters M, Van Camp G, Pauwels P, Op de Beeck K, Deschoolmeester V. Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. Drugs 2015;75:1739-56. [PMID: 26347132 DOI: 10.1007/s40265-015-0459-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
121 Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S. Targeting CDK9 for treatment of colorectal cancer. Mol Oncol 2019;13:2178-93. [PMID: 31398271 DOI: 10.1002/1878-0261.12559] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
122 Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012;30:3545-51. [PMID: 22927525 DOI: 10.1200/JCO.2012.41.9572] [Cited by in Crossref: 92] [Cited by in F6Publishing: 32] [Article Influence: 10.2] [Reference Citation Analysis]
123 Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One 2013;8:e56205. [PMID: 23441167 DOI: 10.1371/journal.pone.0056205] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
124 Doroshow DB, Doroshow JH. Genomics and the History of Precision Oncology. Surg Oncol Clin N Am 2020;29:35-49. [PMID: 31757312 DOI: 10.1016/j.soc.2019.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
125 Serpe L, Gallicchio M, Canaparo R, Dosio F. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmgenomics Pers Med 2014;7:31-42. [PMID: 24516337 DOI: 10.2147/PGPM.S58374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
126 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
127 Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D. Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Hum Genome Var 2015;2:15009. [PMID: 27081524 DOI: 10.1038/hgv.2015.9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
128 Lim R, Sun Y, Im SA, Hsieh RK, Yau TK, Bonaventura A, Cheirsilpa A, Esser R, Mueser M, Advani S. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroenterol 2011;17:1879-88. [PMID: 21528063 DOI: 10.3748/wjg.v17.i14.1879] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
129 Biteghe FAN, Mungra N, Chalomie NET, Ndong JC, Engohang-Ndong J, Vignaux G, Padayachee E, Naran K, Barth S. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. Oncotarget 2020;11:3531-57. [PMID: 33014289 DOI: 10.18632/oncotarget.27730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
130 Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008;26:956-963. [PMID: 18798075 DOI: 10.1080/07357900802132550] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
131 Zhou Y, Zhang J, Dan Pu, Bi F, Chen Y, Liu J, Li Q, Gou H, Wu B, Qiu M. Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer. Anticancer Drugs 2019;30:195-200. [PMID: 30570508 DOI: 10.1097/CAD.0000000000000726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
132 Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010;12 Suppl 2:S1. [PMID: 21050422 DOI: 10.1186/bcr2572] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
133 Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal. 2009;21:1255-1268. [PMID: 19258037 DOI: 10.1016/j.cellsig.2009.02.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
134 Miyamoto Y, Muguruma N, Fujimoto S, Okada Y, Kida Y, Nakamura F, Tanaka K, Nakagawa T, Kitamura S, Okamoto K, Miyamoto H, Sato Y, Takayama T. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models. Cancer Sci 2019;110:1921-30. [PMID: 30973663 DOI: 10.1111/cas.14020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
135 Creasy JM, Midya A, Chakraborty J, Adams LB, Gomes C, Gonen M, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI, Do RKG, Simpson AL. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. Eur Radiol 2019;29:458-67. [PMID: 29922934 DOI: 10.1007/s00330-018-5542-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
136 Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, Thèzenas S. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005;5:62. [PMID: 15967033 DOI: 10.1186/1471-2407-5-62] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
137 Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T, Ichimura T, Ogura M, Ozaka M, Suenaga M, Shinozaki E, Chin K, Yamaguchi K. Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. Oncotarget 2018;9:15219-27. [PMID: 29632638 DOI: 10.18632/oncotarget.24635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
138 Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, van't Veer L, Salazar R, Bernards R, Capella G. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013;62:540-9. [PMID: 22798500 DOI: 10.1136/gutjnl-2012-302423] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 9.8] [Reference Citation Analysis]
139 de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM. Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene 2019;38:1477-88. [PMID: 30305724 DOI: 10.1038/s41388-018-0522-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
140 Troiani T, Martinelli E, Morgillo F, Capasso A, Nappi A, Sforza V, Ciardiello F. Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol 2013;5:51-72. [PMID: 23323147 DOI: 10.1177/1758834012462462] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
141 Kurniali PC, Hrinczenko B, Al-Janadi A. Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol. 2014;20:1910-1922. [PMID: 24616568 DOI: 10.3748/wjg.v20.i8.1910] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
142 Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Mod Pathol 2015;28:1390-9. [PMID: 26226847 DOI: 10.1038/modpathol.2015.86] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
143 Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65-72. [PMID: 21960318 DOI: 10.1007/s00432-011-1061-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
144 Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C. Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. Br J Cancer 2008;98:900-6. [PMID: 18319714 DOI: 10.1038/sj.bjc.6604265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
145 Rawla P, Barsouk A, Hadjinicolaou AV, Barsouk A. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Med Sci (Basel) 2019;7:E83. [PMID: 31366129 DOI: 10.3390/medsci7080083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
146 Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK, Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim R, Agarwal S, Sengupta S, Sundaram M, Majumder PK. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 2015;6:6169. [PMID: 25721094 DOI: 10.1038/ncomms7169] [Cited by in Crossref: 164] [Cited by in F6Publishing: 134] [Article Influence: 27.3] [Reference Citation Analysis]
147 Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008;10:493-495. [PMID: 18832458 DOI: 10.2353/jmoldx.2008.080105] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
148 Bandrés E, Zárate R, Ramirez N, Abajo A, Bitarte N, Garíia-Foncillas J. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. World J Gastroenterol 2007;13:5888-901. [PMID: 17990354 DOI: 10.3748/wjg.v13.i44.5888] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
149 Maréchal R, De Schutter J, Nagy N, Demetter P, Lemmers A, Devière J, Salmon I, Tejpar S, Van Laethem JL. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer. 2010;10:340. [PMID: 20591136 DOI: 10.1186/1471-2407-10-340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
150 Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel) 2019;11:E857. [PMID: 31226812 DOI: 10.3390/cancers11060857] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 14.5] [Reference Citation Analysis]
151 Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109-1117. [PMID: 18337601 DOI: 10.1056/nejmoa074943] [Cited by in Crossref: 973] [Cited by in F6Publishing: 308] [Article Influence: 74.8] [Reference Citation Analysis]
152 Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H, Yu J, Lu J. Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol 2012;33:2209-16. [PMID: 22890830 DOI: 10.1007/s13277-012-0482-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
153 Arnold D, Stein A. New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. Drugs. 2013;73:883-891. [PMID: 23743737 DOI: 10.1007/s40265-013-0076-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
154 Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006;12:3297-305. [PMID: 16733844 DOI: 10.3748/wjg.v12.i21.3297] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
155 Al-Shamsi HO, Alhazzani W, Wolff RA. Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. J Gastrointest Oncol 2015;6:314-21. [PMID: 26029459 DOI: 10.3978/j.issn.2078-6891.2015.016] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
156 Xing M, Wang X, Chi Y, Zhou D. Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget 2016;7:28262-72. [PMID: 27058423 DOI: 10.18632/oncotarget.8596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
157 Nagamine A, Araki T, Nagano D, Miyazaki M, Yamamoto K. L-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines. Oncol Lett 2019;17:4710-6. [PMID: 30944657 DOI: 10.3892/ol.2019.10075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
158 Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 2011;154:111-21. [PMID: 21554263 DOI: 10.1111/j.1365-2141.2011.08714.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
159 Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132. [PMID: 16225697 DOI: 10.1186/1471-2407-5-132] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 4.8] [Reference Citation Analysis]
160 Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ, Kerin MJ. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis. 2011;26:1415-1422. [PMID: 21739196 DOI: 10.1007/s00384-011-1279-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 6.4] [Reference Citation Analysis]
161 Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ, Fidler IJ, Langley RR. Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol 2008;173:205-16. [PMID: 18583324 DOI: 10.2353/ajpath.2008.071147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
162 Razavi ZS, Asgarpour K, Mahjoubin-Tehran M, Rasouli S, Khan H, Shahrzad MK, Hamblin MR, Mirzaei H. Angiogenesis-related non-coding RNAs and gastrointestinal cancer. Mol Ther Oncolytics 2021;21:220-41. [PMID: 34095461 DOI: 10.1016/j.omto.2021.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
163 Ow TJ, Sandulache VC, Skinner HD, Myers JN. Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. Cancer 2013;119:3914-28. [PMID: 24037788 DOI: 10.1002/cncr.28304] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
164 Streb J, Püsküllüoğlu M, Glanowska I, Ochenduszko S, Konopka K, Łupkowski R, Michalowska-Kaczmarczyk A, Bochenek-Cibor J, Majka M, Krzemieniecki K. Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature. Oncol Lett 2015;10:3749-55. [PMID: 26788202 DOI: 10.3892/ol.2015.3800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
165 Solassol J, Ramos J, Crapez E, Saifi M, Mangé A, Vianès E, Lamy PJ, Costes V, Maudelonde T. KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci 2011;12:3191-204. [PMID: 21686179 DOI: 10.3390/ijms12053191] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
166 Hsu JC, Lin JY, Lin PC, Lee YC. Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. PLoS One 2019;14:e0225938. [PMID: 31830075 DOI: 10.1371/journal.pone.0225938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
167 Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol 2016;173:1407-24. [PMID: 26833433 DOI: 10.1111/bph.13450] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
168 Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, Graves-Deal R, Revetta F, Foutch AC, Rothenberg ML, Washington MK. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res. 2008;14:1182-1191. [PMID: 18281553 DOI: 10.1158/1078-0432.ccr-07-1216] [Cited by in Crossref: 71] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
169 Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-499. [PMID: 19536109 DOI: 10.1038/nrc2645.] [Reference Citation Analysis]
170 Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Sasaki T, Takeno S, Yamashita Y. Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. Case Rep Oncol 2014;7:117-21. [PMID: 24707258 DOI: 10.1159/000360132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
171 Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res. 2013;5:387-400. [PMID: 24294007 DOI: 10.2147/cmar.s35025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
172 Røsland GV, Engelsen AS. Novel points of attack for targeted cancer therapy. Basic Clin Pharmacol Toxicol 2015;116:9-18. [PMID: 25154903 DOI: 10.1111/bcpt.12313] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
173 Palleschi M, Maltoni R, Barzotti E, Melegari E, Curcio A, Cecconetto L, Sarti S, Manunta S, Rocca A. Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report. World J Clin Cases 2020;8:517-21. [PMID: 32110660 DOI: 10.12998/wjcc.v8.i3.517] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, Faviana P, Sensi E, Lupi C, Fontanini G, Basolo F, Di Paolo A, Danesi R, Falcone A, Bocci G. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol 2014;9:205-14. [PMID: 23821377 DOI: 10.1007/s11523-013-0284-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
175 Choi YW, Song YS, Lee H, Yi K, Kim YB, Suh KW, Lee D. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. Medicine (Baltimore) 2016;95:e3321. [PMID: 27082577 DOI: 10.1097/MD.0000000000003321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
176 Valentí Moreno V, Brunet Vidal J, Manzano Alemany H, Salud Salvia A, Llobera Serentill M, Cabezas Montero I, Servitja Tormo S, Sopena Bert E, Gumà Padró J. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clin Transl Oncol 2006;8:208-12. [PMID: 16648121 DOI: 10.1007/s12094-006-0012-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
177 Phua LC, Ng HW, Yeo AH, Chen E, Lo MS, Cheah PY, Chan EC, Koh PK, Ho HK. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncol Lett 2015;10:2519-26. [PMID: 26622882 DOI: 10.3892/ol.2015.3560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
178 Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw 2011;9:1293-302. [PMID: 22056657 DOI: 10.6004/jnccn.2011.0105] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
179 Milano G, Spano JP, Leyland-Jones B. EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer 2008;99:1-5. [PMID: 18506149 DOI: 10.1038/sj.bjc.6604373] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
180 Marquardt F, Rödel F, Capalbo G, Weiss C, Rödel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol. 2009;185:371-378. [PMID: 19506820 DOI: 10.1007/s00066-009-1936-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
181 Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014;113:376-82. [PMID: 24053120 DOI: 10.1111/bju.12420] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
182 Gil-Bazo I. Novel translational strategies in colorectal cancer research. World J Gastroenterol 2007;13:5902-10. [PMID: 17990355 DOI: 10.3748/wjg.v13.i44.5902] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
183 Opasic L, Zhou D, Werner B, Dingli D, Traulsen A. How many samples are needed to infer truly clonal mutations from heterogenous tumours? BMC Cancer 2019;19:403. [PMID: 31035962 DOI: 10.1186/s12885-019-5597-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
184 Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, Milano G. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011;11:496. [PMID: 22117530 DOI: 10.1186/1471-2407-11-496] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
185 Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol 2014;20:6102-12. [PMID: 24876732 DOI: 10.3748/wjg.v20.i20.6102] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
186 Potthoff K, Habl G, Bruckner T, Suppan C, Hassel J, Jäger D, Indorf M, Debus J. Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial. BMC Cancer 2014;14:270. [PMID: 24742019 DOI: 10.1186/1471-2407-14-270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Wild AT, Yamada Y. Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer. Visc Med 2017;33:54-61. [PMID: 28612018 DOI: 10.1159/000454685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
188 Hu Y, Pan C, Hu J, Zhang S. The role of Reg IV in colorectal cancer, as a potential therapeutic target. Contemp Oncol (Pozn) 2015;19:261-4. [PMID: 26557771 DOI: 10.5114/wo.2015.54385] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
189 Puglisi MA, Tesori V, Lattanzi W, Gasbarrini GB, Gasbarrini A. Colon cancer stem cells: controversies and perspectives. World J Gastroenterol 2013;19:2997-3006. [PMID: 23716979 DOI: 10.3748/wjg.v19.i20.2997] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
190 Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol 2009;94:383-8. [PMID: 19330289 DOI: 10.1007/s11060-009-9862-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
191 Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 2008;98:71-6. [PMID: 18059397 DOI: 10.1038/sj.bjc.6604121] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
192 Kuroda S, Tam J, Roth JA, Sokolov K, Ramesh R. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine 2014;9:3825-39. [PMID: 25143731 DOI: 10.2147/IJN.S65990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
193 Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther 2012;13:935-45. [PMID: 22785204 DOI: 10.4161/cbt.20846] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
194 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group., Cancer Research UK., Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO)., Australasian Gastro-Intestinal Trials Group (AGITG)., Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9] [Cited by in Crossref: 1305] [Cited by in F6Publishing: 449] [Article Influence: 100.4] [Reference Citation Analysis]
195 Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E752. [PMID: 28368335 DOI: 10.3390/ijms18040752] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
196 Wang J, Hollingshead J, El-Masry N, Horncastle D, Talbot I, Tomlinson I, Alison MR, El-Bahrawy M. Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients. J Gastrointest Cancer 2012;43:444-55. [PMID: 21989899 DOI: 10.1007/s12029-011-9330-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
197 Lv ZC, Ning JY, Chen HB. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. Tumour Biol 2014;35:11741-50. [PMID: 25417200 DOI: 10.1007/s13277-014-2227-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
198 Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37:57. [PMID: 29534749 DOI: 10.1186/s13046-018-0719-1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 21.3] [Reference Citation Analysis]
199 Saiura A, Yamamoto J, Koga R, Kokudo N, Seki M, Oya M, Ueno M, Kuroyanagi H, Fujimoto Y, Natori T, Yamaguchi T, Muto T. Outcome after hepatic resection of solitary liver metastasis from colorectal cancer in the caudate lobe. World J Surg 2007;31:2378-83. [PMID: 17912586 DOI: 10.1007/s00268-007-9250-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
200 Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106-116. [PMID: 26175926 DOI: 10.7497/j.issn.2095-3941.2015.0030] [Cited by in F6Publishing: 149] [Reference Citation Analysis]
201 Assoun S, Lemiale V, Azoulay E. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med 2019;45:988-97. [PMID: 31143997 DOI: 10.1007/s00134-019-05650-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
202 Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101:715-721. [PMID: 19603018 DOI: 10.1038/sj.bjc.6605177] [Cited by in Crossref: 376] [Cited by in F6Publishing: 334] [Article Influence: 31.3] [Reference Citation Analysis]
203 Das D, Preet R, Mohapatra P, Satapathy SR, Kundu CN. 1,3-Bis(2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells. World J Gastroenterol. 2013;19:7374-7388. [PMID: 24259968 DOI: 10.3748/wjg.v19.i42.7374] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
204 Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006;11:3-11. [PMID: 16947082 DOI: 10.1007/s10911-006-9008-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
205 Cao Y, Wang X. Effects of molecular markers on the treatment decision and prognosis of colorectal cancer: a narrative review. J Gastrointest Oncol 2021;12:1191-6. [PMID: 34295567 DOI: 10.21037/jgo-21-230] [Reference Citation Analysis]
206 Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs 2019;79:633-45. [PMID: 30968289 DOI: 10.1007/s40265-019-01113-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
207 Carlsson M, Braddock M, Li Y, Wang J, Xu W, White N, Megally A, Hunter G, Colice G. Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. Drug Saf 2019;42:769-84. [PMID: 30649752 DOI: 10.1007/s40264-018-00788-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
208 Li Y, Chen X, Li W, Ye Y, Du X, Sun S, Liu L, Zhang H. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. Front Oncol 2021;11:684309. [PMID: 34109130 DOI: 10.3389/fonc.2021.684309] [Reference Citation Analysis]
209 Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 2018;13:e0193640. [PMID: 29522543 DOI: 10.1371/journal.pone.0193640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
210 Kam AE, Pendurti G, Shah UH, Ghalib MH, Chaudhary I, Chuy J, Rajdev L, Kaubisch A, Aparo S, Mantzaris I, Goel S. Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. Invest New Drugs 2019;37:490-7. [PMID: 30315379 DOI: 10.1007/s10637-018-0675-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39:210. [PMID: 33028357 DOI: 10.1186/s13046-020-01715-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
212 Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS; Gynecologic Oncology Group. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:493-9. [PMID: 18191993 DOI: 10.1016/j.ygyno.2007.11.029] [Cited by in Crossref: 93] [Cited by in F6Publishing: 73] [Article Influence: 7.2] [Reference Citation Analysis]
213 Cohen G, Lecht S, Arien-Zakay H, Ettinger K, Amsalem O, Oron-Herman M, Yavin E, Prus D, Benita S, Nissan A, Lazarovici P. Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factor. PLoS One. 2012;7:e48803. [PMID: 23144978 DOI: 10.1371/journal.pone.0048803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
214 Atzori F, Traina TA, Ionta MT, Massidda B. Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 2009;4:255-266. [PMID: 19876700 DOI: 10.1007/s11523-009-0123-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
215 Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep. 2010;12:160-167. [PMID: 20425075 DOI: 10.1007/s11912-010-0099-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
216 Mody K, Strauss E, Lincer R, Frank RC. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer 2010;10:570. [PMID: 20961434 DOI: 10.1186/1471-2407-10-570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
217 Iwamoto T, Okamoto A, Ishinaga H, Shimizu K, Gayle AA, Arai N, Takeuchi K, Okuda M. A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils. Cancer Med 2016;5:1004-12. [PMID: 26880699 DOI: 10.1002/cam4.658] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
218 Li X, Lu Y, Lu H, Luo J, Hong Y, Fan Z. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget 2015;6:11507-18. [PMID: 25871473 DOI: 10.18632/oncotarget.3432] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
219 Pan JH, Zhou H, Zhu SB, Huang JL, Zhao XX, Ding H, Pan YL. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. Cancer Manag Res 2018;10:2289-301. [PMID: 30122982 DOI: 10.2147/CMAR.S170105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
220 Cercek A, Saltz L. Evolving treatment of advanced colorectal cancer. Curr Oncol Rep. 2010;12:153-159. [PMID: 20425074 DOI: 10.1007/s11912-010-0096-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
221 Thangarasa T, Gotfrit J, Goodwin RA, Tang PA, Clemons M, Imbulgoda A, Vickers MM. Epidermal growth factor receptor inhibitor-induced hypomagnesemia: a survey of practice patterns among Canadian gastrointestinal medical oncologists. Curr Oncol 2019;26:e162-6. [PMID: 31043822 DOI: 10.3747/co.26.4591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
222 Bhutiani N, Akinwande O, Martin RC. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. World J Surg. 2016;40:1178-1190. [PMID: 26711640 DOI: 10.1007/s00268-015-3386-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
223 Ashraf SQ, Umana P, Mössner E, Ntouroupi T, Brünker P, Schmidt C, Wilding JL, Mortensen NJ, Bodmer WF. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009;101:1758-68. [PMID: 19904275 DOI: 10.1038/sj.bjc.6605355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
224 Yasunaga M, Manabe S, Tarin D, Matsumura Y. Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci 2013;104:231-7. [PMID: 23121194 DOI: 10.1111/cas.12062] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
225 Thalheimer A, Otto C, Bueter M, Illert B, Gattenlohner S, Gasser M, Meyer D, Fein M, Germer CT, Waaga-Gasser AM. The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer. BMC Cancer 2009;9:29. [PMID: 19166621 DOI: 10.1186/1471-2407-9-29] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
226 Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X. The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol 2013;4:72-81. [PMID: 23451330 DOI: 10.3978/j.issn.2078-6891.2012.044] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
227 Hebbar M, Ychou M, Ducreux M. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2009;135:749-52. [PMID: 19343364 DOI: 10.1007/s00432-009-0580-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
228 Dupont B, Mariotte D, Dugué AE, Clarisse B, Grellard JM, Babin E, Chauffert B, Dakpé S, Moldovan C, Bouhier-Leporrier K, Reimund JM, Di Fiore F, Zanetta S, Mailliez A, Do P, Peytier A, Galais MP, Florescu C, Schott R, Le Mauff B, Gervais R. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. Br J Clin Pharmacol 2017;83:623-31. [PMID: 27662818 DOI: 10.1111/bcp.13140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
229 Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol. 2016;8:642-655. [PMID: 27672422 DOI: 10.4251/wjgo.v8.i9.642] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
230 Veltri A, Guarnieri T, Gazzera C, Busso M, Solitro F, Fora G, Racca P. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med. 2012;117:1139-1151. [PMID: 22430677 DOI: 10.1007/s11547-012-0803-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
231 Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 2009;9:112. [PMID: 19366444 DOI: 10.1186/1471-2407-9-112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
232 Wei L, Chen J, Wen J, Wu D, Ma X, Chen Z, Huang J. Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. Med Sci Monit 2020;26:e919031. [PMID: 32062671 DOI: 10.12659/MSM.919031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Elbadawy M, Usui T, Yamawaki H, Sasaki K. Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer. Cancers (Basel) 2018;10:E164. [PMID: 29843359 DOI: 10.3390/cancers10060164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
234 Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations. Clin Pharmacokinet 2009;48:477-87. [PMID: 19691369 DOI: 10.2165/11313400-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
235 Wang L, Jiang CF, Li DM, Ge X, Shi ZM, Li CY, Liu X, Yin Y, Zhen L, Liu LZ, Jiang BH. MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget 2016;7:2660-71. [PMID: 26673620 DOI: 10.18632/oncotarget.6545] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
236 van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31. [PMID: 18802721 DOI: 10.1007/s00428-008-0665-y] [Cited by in Crossref: 209] [Cited by in F6Publishing: 183] [Article Influence: 16.1] [Reference Citation Analysis]
237 Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
238 Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget 2017;8:4277-88. [PMID: 28032592 DOI: 10.18632/oncotarget.13834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
239 Kim HK, Hwang HL, Park SY, Lee KM, Park WC, Kim HS, Um TH, Hong YJ, Lee JK, Joo SY, Seoh JY, Song YW, Kim SY, Kim YN, Hong KM. Simple and versatile molecular method of copy-number measurement using cloned competitors. PLoS One 2013;8:e69414. [PMID: 23936009 DOI: 10.1371/journal.pone.0069414] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
240 Cuneo KC, Nyati MK, Ray D, Lawrence TS. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther 2015;154:67-77. [PMID: 26205191 DOI: 10.1016/j.pharmthera.2015.07.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
241 Lin Z, Zhang L, Zhou J, Zheng J. Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transition. Mol Med Rep 2019;20:3735-45. [PMID: 31485652 DOI: 10.3892/mmr.2019.10597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
242 Asting AG, Farivar A, Iresjö BM, Svensson H, Gustavsson B, Lundholm K. EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer. BMC Cancer 2013;13:511. [PMID: 24171795 DOI: 10.1186/1471-2407-13-511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
243 Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol 2017;30:613-21. [PMID: 29118555 DOI: 10.20524/aog.2017.0191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
244 Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, Lee HS. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014;9:e98528. [PMID: 24879338 DOI: 10.1371/journal.pone.0098528] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 13.0] [Reference Citation Analysis]
245 Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget 2015;6:24780-96. [PMID: 26318427 DOI: 10.18632/oncotarget.4959] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
246 He P, Zou Y, Qiu J, Yang T, Peng L, Zhang X. Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer. J Oncol 2021;2021:6687291. [PMID: 34239564 DOI: 10.1155/2021/6687291] [Reference Citation Analysis]
247 Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010;15:1002-8. [PMID: 20709888 DOI: 10.1634/theoncologist.2010-0063] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
248 Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol 2016;70:771-5. [PMID: 27178450 DOI: 10.1016/j.eururo.2016.04.037] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]
249 Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 2015;106:1722-9. [PMID: 26426205 DOI: 10.1111/cas.12827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
250 Nestor M. Effect of cetuximab treatment in squamous cell carcinomas. Tumour Biol 2010;31:141-7. [PMID: 20358427 DOI: 10.1007/s13277-010-0018-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
251 Zhou Y, Zhao L, Marks JD. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys 2012;526:107-13. [PMID: 22627065 DOI: 10.1016/j.abb.2012.05.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
252 Nolan-Stevaux O, Truitt MC, Pahler JC, Olson P, Guinto C, Lee DC, Hanahan D. Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer 2010;1:125-41. [PMID: 20975924 DOI: 10.1177/1947601909358722] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
253 Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008;8:120. [PMID: 18439246 DOI: 10.1186/1471-2407-8-120] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
254 Yang Z, Zhao N, Chen D, Wei K, Su N, Huang JF, Xu HQ, Duan GJ, Fu WL, Huang Q. Improved detection of BRAF V600E using allele-specific PCR coupled with external and internal controllers. Sci Rep 2017;7:13817. [PMID: 29061997 DOI: 10.1038/s41598-017-14140-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
255 Ladd AC, O’Sullivan-Mejia E, Lea T, Perry J, Dumur CI, Dragoescu E, Garrett CT, Powers CN. Preservation of fine-needle aspiration specimens for future use in RNA-based molecular testing. Cancer Cytopathol. 2011;119:102-110. [PMID: 21287691 DOI: 10.1002/cncy.20130] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
256 Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs 2015;7:255-64. [PMID: 25587678 DOI: 10.4161/19420862.2014.985160] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
257 Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658-673. [PMID: 23729478 DOI: 10.1158/2159-8290.cd-12-0558] [Cited by in Crossref: 421] [Cited by in F6Publishing: 239] [Article Influence: 52.6] [Reference Citation Analysis]
258 Koncina E, Haan S, Rauh S, Letellier E. Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers (Basel). 2020;12. [PMID: 32019056 DOI: 10.3390/cancers12020319] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 25.0] [Reference Citation Analysis]
259 Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009;100:1379-84. [PMID: 19401697 DOI: 10.1038/sj.bjc.6605043] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
260 Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009;113:21-7. [PMID: 19162309 DOI: 10.1016/j.ygyno.2008.12.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
261 Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol 2013;10:571-87. [PMID: 23999218 DOI: 10.1038/nrclinonc.2013.158] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 18.5] [Reference Citation Analysis]
262 Alexander HR, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009;16:1852-1859. [PMID: 19434456 DOI: 10.1245/s10434-009-0482-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
263 Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:1941. [PMID: 33920531 DOI: 10.3390/cancers13081941] [Reference Citation Analysis]
264 Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460. [PMID: 20018966 DOI: 10.1056/nejmra0804588] [Cited by in Crossref: 1098] [Cited by in F6Publishing: 637] [Article Influence: 99.8] [Reference Citation Analysis]
265 Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Invest New Drugs 2017;35:68-78. [PMID: 27853996 DOI: 10.1007/s10637-016-0399-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
266 Choi Y, Won YJ, Lee S, Kim A, Kim Y, Park WY, Jo HJ, Song GA, Kwon CH, Park DY. Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer. Transl Oncol 2018;11:764-70. [PMID: 29689458 DOI: 10.1016/j.tranon.2018.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
267 Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol 2020;12:1758835920910913. [PMID: 32201506 DOI: 10.1177/1758835920910913] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
268 Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Röcken C, Dietel M. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12:35-42. [PMID: 20007841 DOI: 10.2353/jmoldx.2010.090079] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
269 Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009;50:1116-23. [PMID: 19525473 DOI: 10.2967/jnumed.109.061820] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
270 Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007;96:206-12. [PMID: 17242694 DOI: 10.1038/sj.bjc.6603561] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
271 Pérez-Ruiz E, Rueda A, Pereda T, Alcaide J, Bautista D, Rivas-Ruiz F, Villatoro R, Pérez D, Redondo M. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. Tumour Biol. 2012;33:1829-1835. [PMID: 22791568 DOI: 10.1007/s13277-012-0442-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
272 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014;13:242. [PMID: 25344208 DOI: 10.1186/1476-4598-13-242] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
273 Saif MW, Kontny E, Syrigos KN, Shahrokni A. The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol 2011;2011:125467. [PMID: 21772841 DOI: 10.1155/2011/125467] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
274 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
275 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
276 Montomoli J, Hamilton-Dutoit SJ, Frøslev T, Taylor A, Erichsen R. Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study. Clin Exp Gastroenterol 2012;5:167-71. [PMID: 23028236 DOI: 10.2147/CEG.S34725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
277 Goel G, Sun W. Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014;33:445-57. [PMID: 25189717 DOI: 10.5732/cjc.014.10123] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
278 Liu K, Jin M, Ye S, Yan S. CHI3L1 promotes proliferation and improves sensitivity to cetuximab in colon cancer cells by down-regulating p53. J Clin Lab Anal 2020;34:e23026. [PMID: 31536166 DOI: 10.1002/jcla.23026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
279 Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54:1194-202. [PMID: 16009693 DOI: 10.1136/gut.2004.062745] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
280 Palka KT, Slebos RJ, Chung CH. Update on molecular diagnostic tests in head and neck cancer. Semin Oncol 2008;35:198-210. [PMID: 18544435 DOI: 10.1053/j.seminoncol.2008.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
281 Datta J, Narayan RR, Goldman DA, Chatila WK, Gonen M, Strong J, Balachandran VP, Drebin JA, Kingham TP, Jarnagin WR, Schultz N, Kemeny NE, D'Angelica MI. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy. Ann Surg 2020. [PMID: 33214457 DOI: 10.1097/SLA.0000000000004613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
282 Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T. Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncol Lett 2013;5:249-54. [PMID: 23255930 DOI: 10.3892/ol.2012.963] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
283 Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25:85-101. [PMID: 20430953 DOI: 10.1152/physiol.00045.2009] [Cited by in Crossref: 208] [Cited by in F6Publishing: 195] [Article Influence: 18.9] [Reference Citation Analysis]
284 Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs 2007;67:1851-67. [PMID: 17722954 DOI: 10.2165/00003495-200767130-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
285 Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [PMID: 19998273 DOI: 10.1002/cncr.24760] [Cited by in Crossref: 1205] [Cited by in F6Publishing: 1065] [Article Influence: 109.5] [Reference Citation Analysis]
286 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
287 D'Souza JW, Robinson MK. Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther 2015;15:1015-21. [PMID: 25936923 DOI: 10.1517/14712598.2015.1042362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
288 Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer. 2006;94:1136-1143. [PMID: 16570047 DOI: 10.1038/sj.bjc.6603055] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
289 Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, Diagaradjane P, Wei C, Baladandayuthapani V, Krishnan S, Guha S, Aggarwal BB. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res. 2012;18:4942-4953. [PMID: 22832932 DOI: 10.1158/1078-0432.ccr-11-2805] [Cited by in Crossref: 103] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
290 Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, Letai A, Medema JP. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014;21:1170-1177. [PMID: 24682005 DOI: 10.1038/cdd.2014.37] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 10.1] [Reference Citation Analysis]
291 Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 2016;22:887-94. [PMID: 26811634 DOI: 10.3748/wjg.v22.i2.887] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
292 Horisberger K, Hofheinz RD, Palma P, Volkert AK, Rothenhoefer S, Wenz F, Hochhaus A, Post S, Willeke F. Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity? Int J Colorectal Dis. 2008;23:257-264. [PMID: 18071720 DOI: 10.1007/s00384-007-0408-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
293 Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 2011;17:472-482. [PMID: 21098338 DOI: 10.1158/1078-0432.ccr-10-0568] [Cited by in Crossref: 127] [Cited by in F6Publishing: 76] [Article Influence: 11.5] [Reference Citation Analysis]
294 Hartimath SV, El-Sayed A, Makhlouf A, Bernhard W, Gonzalez C, Hill W, Parada AC, Barreto K, Geyer CR, Fonge H. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget 2019;10:1031-44. [PMID: 30800216 DOI: 10.18632/oncotarget.26613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
295 Guan M, Zhou YP, Sun JL, Chen SC. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int 2015;2015:428169. [PMID: 26075239 DOI: 10.1155/2015/428169] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
296 Biteghe FAN, Chalomie NET, Mungra N, Vignaux G, Gao N, Vergeade A, Okem A, Naran K, Ndong JC, Barth S. Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. Biomedicines 2020;8:E327. [PMID: 32899183 DOI: 10.3390/biomedicines8090327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
297 Tang XM, Chen H, Li Q, Song Y, Zhang S, Xu XS, Xu Y, Chen S. Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC. Onco Targets Ther 2018;11:123-9. [PMID: 29343971 DOI: 10.2147/OTT.S149716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Spindler KL, Christensen IJ, Nielsen HJ, Jakobsen A, Brünner N. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. Tumour Biol 2015;36:4301-8. [PMID: 25608838 DOI: 10.1007/s13277-015-3069-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
299 Ziv E, Bergen M, Yarmohammadi H, Boas FE, Petre EN, Sofocleous CT, Yaeger R, Solit DB, Solomon SB, Erinjeri JP. PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget 2017;8:23529-38. [PMID: 28206962 DOI: 10.18632/oncotarget.15278] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
300 Dupont B, Mariotte D, Moldovan C, Grellard JM, Vergnaud MC, Laroche D, Gervais R. Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test. Clin Med Insights Oncol 2014;8:91-4. [PMID: 25089092 DOI: 10.4137/CMO.S13897] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
301 Shimada Y, Kameyama H, Nagahashi M, Ichikawa H, Muneoka Y, Yagi R, Tajima Y, Okamura T, Nakano M, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Hayashida T, Takaishi H, Kitagawa Y, Oki E, Konishi T, Ishida F, Kudo SE, Ring JE, Protopopov A, Lyle S, Ling Y, Okuda S, Ishikawa T, Akazawa K, Takabe K, Wakai T. Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget 2017;8:93567-79. [PMID: 29212173 DOI: 10.18632/oncotarget.20510] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
302 Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer 2013;13:599. [PMID: 24330663 DOI: 10.1186/1471-2407-13-599] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
303 Kasper S, Reis H, Ziegler S, Nothdurft S, Mueller A, Goetz M, Wiesweg M, Phasue J, Ting S, Wieczorek S, Even A, Worm K, Pogorzelski M, Breitenbuecher S, Meiler J, Paul A, Trarbach T, Schmid KW, Breitenbuecher F, Schuler M. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. Oncotarget 2017;8:45898-917. [PMID: 28507280 DOI: 10.18632/oncotarget.17438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
304 Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014;20:4263-75. [PMID: 24764664 DOI: 10.3748/wjg.v20.i15.4263] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
305 Chen P, Wang L, Li H, Liu B, Zou Z. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncol Lett 2013;5:1915-20. [PMID: 23833666 DOI: 10.3892/ol.2013.1301] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
306 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget 2016;7:34811-23. [PMID: 27166185 DOI: 10.18632/oncotarget.9187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
307 Ishimura E, Nakagawa T, Moriwaki K, Hirano S, Matsumori Y, Asahi M. Augmented O-GlcNAcylation of AMP-activated kinase promotes the proliferation of LoVo cells, a colon cancer cell line. Cancer Sci 2017;108:2373-82. [PMID: 28973823 DOI: 10.1111/cas.13412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
308 Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014;20:9862-71. [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
309 Stein A, Hiemer S, Schmoll H. Adjuvant Therapy for Early Colon Cancer: Current Status. Drugs 2011;71:2257-75. [DOI: 10.2165/11594490-000000000-00000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
310 Donadon M, Hudspeth K, Cimino M, Di Tommaso L, Preti M, Tentorio P, Roncalli M, Mavilio D, Torzilli G. Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival. J Gastrointest Surg. 2017;21:1226-1236. [PMID: 28536806 DOI: 10.1007/s11605-017-3446-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
311 Mehmood RK, Parker J, Ahmed S, Qasem E, Mohammed AA, Zeeshan M, Jehangir E. Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective. World J Oncol 2014;5:97-108. [PMID: 29147386 DOI: 10.14740/wjon830w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
312 Suzuki S, Dobashi Y, Minato H, Tajiri R, Yoshizaki T, Ooi A. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch 2012;461:271-82. [PMID: 22828828 DOI: 10.1007/s00428-012-1282-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
313 Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer. 2005;92:1846-1849. [PMID: 15870719 DOI: 10.1038/sj.bjc.6602569] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
314 Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamo M, Takahashi M, Komine K, Kato S, Ishioka C. KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. Mol Clin Oncol 2014;2:356-62. [PMID: 24772300 DOI: 10.3892/mco.2014.254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
315 Spartalis C, Schmidt EM, Elmasry M, Schulz GB, Kirchner T, Horst D. In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer. Cancer Sci. 2019;110:2529-2539. [PMID: 31119819 DOI: 10.1111/cas.14077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
316 Moore LM, Holmes KM, Fuller GN, Zhang W. Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model. Chin J Cancer 2011;30:163-72. [PMID: 21352693 DOI: 10.5732/cjc.010.10572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
317 Saridaki Z, Saegart X, De Vriendt V, Hatzidaki D, Palmans S, De Smedt L, De Hertogh G, Tejpar S. KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? Br J Cancer 2015;113:914-20. [PMID: 26325103 DOI: 10.1038/bjc.2015.307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
318 Sanoff HK, Davies JM, Walko C, Irvin W, Buie L, Keller K, Ivanova A, Chiu WK, O'Neil BH, Stinchcombe TE, Dees EC. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. Invest New Drugs 2011;29:978-83. [PMID: 20387090 DOI: 10.1007/s10637-010-9427-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
319 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 327] [Article Influence: 63.2] [Reference Citation Analysis]
320 Jensen AD, Münter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, Haberkorn U, Huber PE, Steins M, Thomas M, Debus J, Herfarth KK. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006;6:122. [PMID: 16681848 DOI: 10.1186/1471-2407-6-122] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
321 Carethers JM. Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol 2008;1:33-42. [PMID: 21180512 DOI: 10.1177/1756283X08093607] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
322 Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten TF. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008;2:349-55. [PMID: 19383356 DOI: 10.1016/j.molonc.2008.09.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
323 Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, Quirke P, Essapen S, Samuel L, Sizer B, Worlding J, Southward K, Hemmings G, Tinkler-Hundal E, Taylor M, Bottomley D, Chambers P, Lawrie E, Lopes A, Beare S. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. Br J Cancer 2017;117:1286-94. [PMID: 28859058 DOI: 10.1038/bjc.2017.294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
324 Inoue Y, Hazama S, Iwamoto S, Miyake Y, Matsuda C, Tsunedomi R, Okayama N, Hinoda Y, Yamasaki T, Suehiro Y, Yoshino S, Sakamoto J, Mishima H, Oka M. FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Mol Diagn Ther 2014;18:541-8. [PMID: 24828248 DOI: 10.1007/s40291-014-0103-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
325 Li Z, Wang M, Yao X, Luo W, Qu Y, Yu D, Li X, Fang J, Huang C. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Target Oncol 2019;14:93-105. [PMID: 30635821 DOI: 10.1007/s11523-018-0616-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
326 Ling BC, Wu J, Miller SJ, Monk KR, Shamekh R, Rizvi TA, Decourten-Myers G, Vogel KS, DeClue JE, Ratner N. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005;7:65-75. [PMID: 15652750 DOI: 10.1016/j.ccr.2004.10.016] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
327 Gao J, Wang TT, Yu JW, Li YY, Shen L. Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients. Chin J Cancer Res. 2011;23:271-275. [PMID: 23357879 DOI: 10.1007/s11670-011-0271-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
328 Taniguchi H, Yamanaka T, Sakai D, Muro K, Yamazaki K, Nakata S, Kimura H, Ruff P, Kim TW, Peeters M, Price T. Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers (Basel) 2020;12:E1715. [PMID: 32605298 DOI: 10.3390/cancers12071715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
329 Liu X, Guo W, Zhang W, Yin J, Zhang J, Zhu X, Liu T, Chen Z, Wang B, Chang J, Lv F, Hong X, Wang H, Wang J, Zhao X, Wu X, Li J. A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. BMC Cancer 2017;17:188. [PMID: 28288572 DOI: 10.1186/s12885-017-3174-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
330 Zheng Z, Hanna N, Onukwugha E, Reese ES, Seal B, Mullins CD. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Med 2014;3:124-33. [PMID: 24403130 DOI: 10.1002/cam4.176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
331 Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465-472. [PMID: 19603024 DOI: 10.1038/sj.bjc.6605164] [Cited by in Crossref: 209] [Cited by in F6Publishing: 193] [Article Influence: 17.4] [Reference Citation Analysis]
332 Suenaga M, Nishina T, Mizunuma N, Yasui H, Ura T, Denda T, Ikeda J, Esaki T, Nishisaki H, Takano Y, Sugiyama Y, Muro K. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). BMC Cancer 2015;15:176. [PMID: 25884814 DOI: 10.1186/s12885-015-1175-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
333 Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19:929-33. [PMID: 19574787 DOI: 10.1111/IGC.0b013e3181a83467] [Cited by in Crossref: 71] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
334 Şahin U, Demirer T. Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumors. Turk J Med Sci 2020;50:1697-706. [PMID: 32178508 DOI: 10.3906/sag-1911-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923-30. [PMID: 18319715 DOI: 10.1038/sj.bjc.6604269] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
336 Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrari D, Lo Re G, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Frassoldati A, Bilancia D, Campanella GA, Signorelli C, Racca P, Benincasa E, Stroppolo ME, Di Costanzo F. Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study. Cancer Med 2016;5:3272-81. [PMID: 27748041 DOI: 10.1002/cam4.888] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
337 Nagakubo Y, Hirotsu Y, Amemiya K, Oyama T, Mochizuki H, Omata M. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR. BMC Med Genomics 2019;12:162. [PMID: 31711486 DOI: 10.1186/s12920-019-0610-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
338 Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010;37:1368-76. [PMID: 20155263 DOI: 10.1007/s00259-009-1370-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
339 Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control 2013;20:32-42. [PMID: 23302905 DOI: 10.1177/107327481302000106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
340 Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC. Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2011;128:2663-72. [PMID: 20715106 DOI: 10.1002/ijc.25609] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
341 Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015;125:4529-4543. [PMID: 26571401 DOI: 10.1172/jci82826] [Cited by in Crossref: 70] [Cited by in F6Publishing: 46] [Article Influence: 11.7] [Reference Citation Analysis]
342 Sastre J, Argilés G, Benavides M, Feliú J, García-Alfonso P, García-Carbonero R, Grávalos C, Guillén-Ponce C, Martínez-Villacampa M, Pericay C. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. Clin Transl Oncol 2014;16:942-53. [PMID: 25223744 DOI: 10.1007/s12094-014-1212-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
343 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
344 Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 2010;10:302. [PMID: 20565817 DOI: 10.1186/1471-2407-10-302] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
345 Wei F, Shin D, Cai X. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. Int J Clin Oncol 2018;23:443-51. [PMID: 29289981 DOI: 10.1007/s10147-017-1231-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
346 Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol. 2010;16:5881-5888. [PMID: 21155011 DOI: 10.3748/wjg.v16.i46.5881] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
347 Masubuchi T, Tada Y, Maruya S, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2015;20:35-44. [PMID: 24553861 DOI: 10.1007/s10147-014-0674-6] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
348 Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011;11:466. [PMID: 22035459 DOI: 10.1186/1471-2407-11-466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
349 Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol 2009;625:41-54. [PMID: 19837059 DOI: 10.1016/j.ejphar.2009.09.067] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
350 Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med 2014;12:203. [PMID: 25369798 DOI: 10.1186/s12916-014-0203-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
351 Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K, Nakagawa K. Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis 2019;8:54. [PMID: 31570699 DOI: 10.1038/s41389-019-0164-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
352 Fukuda K, Saikawa Y, Takahashi M, Takahashi T, Wada N, Kawakubo H, Takeuchi H, Kitagawa Y. Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells. Int J Oncol 2012;40:975-82. [PMID: 22139134 DOI: 10.3892/ijo.2011.1279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
353 Jehn CF, Böning L, Kröning H, Possinger K, Lüftner D. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 2012;106:274-8. [PMID: 22215062 DOI: 10.1038/bjc.2011.554] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
354 Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92. [PMID: 22781697 DOI: 10.1038/nbt.2284] [Cited by in Crossref: 629] [Cited by in F6Publishing: 503] [Article Influence: 69.9] [Reference Citation Analysis]
355 Weng X, Chen W, Hu W, Xu K, Qi L, Chen J, Lu D, Shao Y, Zheng X, Ye C, Zheng S. PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition. Cell Death Dis 2019;10:352. [PMID: 31040266 DOI: 10.1038/s41419-019-1554-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
356 Kalamegam G, Pushparaj PN, Khan F, Sait KH, Anfinan N, Al-Qahtani M. Primary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): Mapping probable mechanisms and targets using systems oncology. Bioinformation 2015;11:529-34. [PMID: 26770026 DOI: 10.6026/97320630011529] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
357 Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss CA, Cheong I, Holdhoff M, Kato Y, Pomper MG, Riggins GJ, Kinzler KW, Diaz LA Jr, Vogelstein B, Zhou S. A robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget 2011;2:59-68. [PMID: 21378416 DOI: 10.18632/oncotarget.227] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
358 Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158:610-620. [PMID: 19732064 DOI: 10.1111/j.1476-5381.2009.00341.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
359 Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther 2012;11:1467-76. [PMID: 22564724 DOI: 10.1158/1535-7163.MCT-11-1038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
360 Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. Cancer Biol Ther 2014;15:826-31. [PMID: 24755613 DOI: 10.4161/cbt.28878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
361 Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One. 2013;8:e65479. [PMID: 23785428 DOI: 10.1371/journal.pone.0065479] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 11.3] [Reference Citation Analysis]
362 Kamel HFM, Al-Amodi HSAB. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics Proteomics Bioinformatics 2017;15:220-35. [PMID: 28813639 DOI: 10.1016/j.gpb.2016.11.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 10.8] [Reference Citation Analysis]
363 Karstensen JG, Klausen PH, Saftoiu A, Vilmann P. Molecular confocal laser endomicroscopy: a novel technique for in vivo cellular characterization of gastrointestinal lesions. World J Gastroenterol. 2014;20:7794-7800. [PMID: 24976717 DOI: 10.3748/wjg.v20.i24.7794] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
364 Chen D, Huang X, Cai J, Guo S, Qian W, Wery JP, Li QX. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. Oncotarget 2015;6:40815-21. [PMID: 26512781 DOI: 10.18632/oncotarget.5886] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
365 Ma J, Yang QL, Ling Y. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer. BMC Cancer 2017;17:132. [PMID: 28196490 DOI: 10.1186/s12885-017-3133-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
366 Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007;97:1469-74. [PMID: 18040272 DOI: 10.1038/sj.bjc.6604053] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
367 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
368 Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008;196:430-41. [PMID: 18718222 DOI: 10.1016/j.amjsurg.2008.04.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
369 Zhang H, Yuan L, Liu L, Yan C, Cheng J, Fu Q, Tong Z, Jiang W, Zheng Y, Zhao P, Zhang G, Fang W. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab. BMC Cancer 2020;20:416. [PMID: 32404198 DOI: 10.1186/s12885-020-06909-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
370 Berdel WE. Unintended Regulatory Caused Early Death-A Difficult Endpoint in Cancer Patient Care and Treatment. Cancers (Basel) 2021;13:1457. [PMID: 33810203 DOI: 10.3390/cancers13061457] [Reference Citation Analysis]
371 Guo P, Yang J, Liu D, Huang L, Fell G, Huang J, Moses MA, Auguste DT. Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis. Sci Adv 2019;5:eaav5010. [PMID: 30906868 DOI: 10.1126/sciadv.aav5010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
372 Xu J, Qin X, Wang J, Zhang S, Zhong Y, Ren L, Wei Y, Zeng S, Wan D, Zheng S; Society of Surgery; Chinese Medical Association; Committee of Colorectal Cancer, Chinese Anti-cancer Association. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol. 2011;137:1379-1396. [PMID: 21796415 DOI: 10.1007/s00432-011-0999-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
373 Yu C, Zhang Y. Development and validation of a prognostic nomogram for early-onset colon cancer. Biosci Rep 2019;39:BSR20181781. [PMID: 31142625 DOI: 10.1042/BSR20181781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
374 Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One 2012;7:e36979. [PMID: 22761653 DOI: 10.1371/journal.pone.0036979] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
375 Della Corte CM, Fasano M, Papaccio F, Ciardiello F, Morgillo F. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines 2014;2:345-58. [PMID: 28548075 DOI: 10.3390/biomedicines2040345] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
376 Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10:167-75. [PMID: 18297364 DOI: 10.1007/s11307-008-0133-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 9.0] [Reference Citation Analysis]
377 Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H. Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells. World J Gastroenterol. 2005;11:5638-5643. [PMID: 16237757 DOI: 10.3748/wjg.v11.i36.5638] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
378 Khan I, Morris S, Hackshaw A, Lee SM. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 2015;5:e006733. [PMID: 26137881 DOI: 10.1136/bmjopen-2014-006733] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
379 Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer. 2012;107:1932-1937. [PMID: 23169296 DOI: 10.1038/bjc.2012.509] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
380 Szaryńska M, Olejniczak A, Kobiela J, Spychalski P, Kmieć Z. Therapeutic strategies against cancer stem cells in human colorectal cancer. Oncol Lett 2017;14:7653-68. [PMID: 29250169 DOI: 10.3892/ol.2017.7261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
381 Kalman B, Szep E, Garzuly F, Post DE. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Neuromolecular Med 2013;15:420-34. [PMID: 23575987 DOI: 10.1007/s12017-013-8229-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
382 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
383 Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. World J Gastrointest Oncol 2016;8:1-7. [PMID: 26798432 DOI: 10.4251/wjgo.v8.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
384 Peacock O, Lee AC, Larvin M, Tufarelli C, Lund JN. MicroRNAs: relevant tools for a colorectal surgeon? World J Surg. 2012;36:1881-1892. [PMID: 22526047 DOI: 10.1007/s00268-012-1603-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
385 Ishiguro M, Watanabe T, Yamaguchi K, Satoh T, Ito H, Seriu T, Sakata Y, Sugihara K. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42:287-94. [PMID: 22327124 DOI: 10.1093/jjco/hys005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
386 Schirripa M, Lenz HJ. Biomarker in Colorectal Cancer. Cancer J 2016;22:156-64. [PMID: 27341592 DOI: 10.1097/PPO.0000000000000190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
387 Schlussel AT, Gagliano RA, Seto-Donlon S, Eggerding F, Donlon T, Berenberg J, Lynch HT. The evolution of colorectal cancer genetics-Part 2: clinical implications and applications. J Gastrointest Oncol. 2014;5:336-344. [PMID: 25276406 DOI: 10.3978/j.issn.2078-6891.2014.068] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
388 Tsujii T, Ogaki T, Nakae K, Imai K, Kise D, Tada S, Ueda H, Moriyama M. Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody. J Pharm Health Care Sci 2016;2:23. [PMID: 27688901 DOI: 10.1186/s40780-016-0060-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
389 Son DJ, Hong JE, Ban JO, Park JH, Lee HL, Gu SM, Hwang JY, Jung MH, Lee DW, Han SB, Hong JT. Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway. Biomed Res Int 2015;2015:397563. [PMID: 26491668 DOI: 10.1155/2015/397563] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
390 Luo D, Smith JA, Meadows NA, Schuh A, Manescu KE, Bure K, Davies B, Horne R, Kope M, DiGiusto DL, Brindley DA. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Front Genet 2015;6:357. [PMID: 26858745 DOI: 10.3389/fgene.2015.00357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
391 López-Gómez M, Cejas P, Merino M, Fernández-Luengas D, Casado E, Feliu J. Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? Clin Transl Oncol 2012;14:641-58. [PMID: 22911546 DOI: 10.1007/s12094-012-0853-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
392 Zhang J, Tang Y, Shen H, Qian B. Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8. J Huazhong Univ Sci Technolog Med Sci 2009;29:273-80. [PMID: 19513605 DOI: 10.1007/s11596-009-0302-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
393 Hong S, Yan Z, Wang H, Ding L, Song Y, Bi M. miR-663b promotes colorectal cancer progression by activating Ras/Raf signaling through downregulation of TNK1. Hum Cell 2020;33:104-15. [PMID: 31758392 DOI: 10.1007/s13577-019-00294-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
394 Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget 2017;8:93856-66. [PMID: 29212194 DOI: 10.18632/oncotarget.21291] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
395 Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R, Barone C. The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol 2011;2011:894704. [PMID: 22190975 DOI: 10.1155/2011/894704] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
396 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
397 Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010;28:4747-4754. [PMID: 20921467 DOI: 10.1200/jco.2009.27.9356] [Cited by in Crossref: 48] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
398 Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, Chen X, Wang F. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 2010;9:2297-308. [PMID: 20682654 DOI: 10.1158/1535-7163.MCT-10-0444] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
399 Kawaguchi Y, Lillemoe HA, Vauthey JN. Gene mutation and surgical technique: Suggestion or more? Surg Oncol 2020;33:210-5. [PMID: 31351766 DOI: 10.1016/j.suronc.2019.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
400 Lemech C, Arkenau HT. Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice. Cancers (Basel) 2011;3:1844-60. [PMID: 24212785 DOI: 10.3390/cancers3021844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
401 Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27:3944-3956. [PMID: 18297114 DOI: 10.1038/onc.2008.19] [Cited by in Crossref: 398] [Cited by in F6Publishing: 340] [Article Influence: 30.6] [Reference Citation Analysis]
402 Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer. 2014;110:1148-1154. [PMID: 24407191 DOI: 10.1038/bjc.2013.813] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
403 Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010;102:500-5. [PMID: 20068568 DOI: 10.1038/sj.bjc.6605521] [Cited by in Crossref: 128] [Cited by in F6Publishing: 114] [Article Influence: 11.6] [Reference Citation Analysis]
404 Solomon VR, Barreto K, Bernhard W, Alizadeh E, Causey P, Perron R, Gendron D, Alam MK, Carr A, Geyer CR, Fonge H. Nimotuzumab Site-Specifically Labeled with 89Zr and 225Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers. Cancers (Basel) 2020;12:E3449. [PMID: 33233524 DOI: 10.3390/cancers12113449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Wang F, Chen Y, Huang L, Liu T, Huang Y, Zhao J, Wang X, Yang K, Ma S, Huang L, To KK, Gu Y, Fu L. Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells. Oncotarget 2015;6:40850-65. [PMID: 26506420 DOI: 10.18632/oncotarget.5813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
406 Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol 2014;140:737-48. [PMID: 24595598 DOI: 10.1007/s00432-014-1626-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
407 Xue F, Liang Y, Li Z, Liu Y, Zhang H, Wen Y, Yan L, Tang Q, Xiao E, Zhang D. MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2. Oncol Lett. 2018;15:813-820. [PMID: 29399149 DOI: 10.3892/ol.2017.7399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
408 Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007;13:527-34. [PMID: 17981505 DOI: 10.1016/j.molmed.2007.10.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 5.5] [Reference Citation Analysis]
409 Eefsen RL, Vermeulen PB, Christensen IJ, Laerum OD, Mogensen MB, Rolff HC, Van den Eynden GG, Høyer-Hansen G, Osterlind K, Vainer B, Illemann M. Growth pattern of colorectal liver metastasis as a marker of recurrence risk. Clin Exp Metastasis 2015;32:369-81. [PMID: 25822899 DOI: 10.1007/s10585-015-9715-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
410 Recondo G Jr, Díaz-Cantón E, de la Vega M, Greco M, Recondo G Sr, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014;6:211-24. [PMID: 25024813 DOI: 10.4251/wjgo.v6.i7.211] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
411 Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN, Zhang W. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A 2009;106:16675-9. [PMID: 19805356 DOI: 10.1073/pnas.0900807106] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
412 Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 2017;17:254-68. [PMID: 28104906 DOI: 10.1038/nrc.2016.140] [Cited by in Crossref: 321] [Cited by in F6Publishing: 260] [Article Influence: 80.3] [Reference Citation Analysis]
413 Li JA, Song C, Rong Y, Kuang T, Wang D, Xu X, Yuan J, Luo K, Qin B, Nowsheen S, Lou Z, Lou W. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle 2018;17:191-9. [PMID: 29157102 DOI: 10.1080/15384101.2017.1405194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
414 Hu Y, Gaedcke J, Emons G, Beissbarth T, Grade M, Jo P, Yeager M, Chanock SJ, Wolff H, Camps J, Ghadimi BM, Ried T. Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery. Genes Chromosomes Cancer 2018;57:140-9. [PMID: 29119627 DOI: 10.1002/gcc.22512] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
415 Zhang H, Liang C, Hou X, Wang L, Zhang D. Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo. Int J Nanomedicine 2016;11:1039-50. [PMID: 27042059 DOI: 10.2147/IJN.S98519] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
416 Iemoto T, Nishiumi S, Kobayashi T, Fujigaki S, Hamaguchi T, Kato K, Shoji H, Matsumura Y, Honda K, Yoshida M. Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncol Lett 2019;17:831-42. [PMID: 30655836 DOI: 10.3892/ol.2018.9731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
417 Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011;21:229-37. [PMID: 21971567 DOI: 10.1016/j.semcancer.2011.09.012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
418 Kim YH, Kim HK, Kim HY, Gawk H, Bae SH, Sim HW, Kang EK, Seoh JY, Jang H, Hong KM. FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer. Cancers (Basel) 2019;11:E1288. [PMID: 31480645 DOI: 10.3390/cancers11091288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
419 Campanella C, Mottolese M, Cianciulli A, Torsello A, Merola R, Sperduti I, Melucci E, Conti S, Diodoro MG, Zeuli M, Paoletti G, Cognetti F, Garufi C. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. J Transl Med 2010;8:36. [PMID: 20398370 DOI: 10.1186/1479-5876-8-36] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
420 Krämer A, Hübner G, Schneeweiss A, Folprecht G, Neben K. Carcinoma of Unknown Primary - an Orphan Disease? Breast Care (Basel) 2008;3:164-70. [PMID: 20824034 DOI: 10.1159/000136001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
421 Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol. 2015;7:47-54. [PMID: 26090075 DOI: 10.4251/wjgo.v7.i6.47] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
422 Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 2006;95:1637-41. [PMID: 17106441 DOI: 10.1038/sj.bjc.6603468] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
423 Chen Q, Chen L, Zhao R, Yang XD, Imran K, Xing CG. Microarray analyses reveal liver metastasis-related genes in metastatic colorectal cancer cell model. J Cancer Res Clin Oncol 2013;139:1169-78. [PMID: 23563852 DOI: 10.1007/s00432-013-1424-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
424 Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal SK. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol 2020;78:916-24. [PMID: 32847703 DOI: 10.1016/j.eururo.2020.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
425 Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, Yang J, Zhou F, Zhou Y. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol 2015;36:3471-82. [PMID: 25542231 DOI: 10.1007/s13277-014-2983-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
426 Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW, Chen KF. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012;16:1037-47. [PMID: 22328001 DOI: 10.1007/s11605-012-1828-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
427 Shin SH, Lim DY, Reddy K, Malakhova M, Liu F, Wang T, Song M, Chen H, Bae KB, Ryu J, Liu K, Lee MH, Bode AM, Dong Z. A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo. EBioMedicine 2017;25:22-31. [PMID: 29033371 DOI: 10.1016/j.ebiom.2017.09.029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
428 Sun L, Ye HY, Zhang YH, Guan YS, Wu H. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol. 2007;13:6115-6118. [PMID: 18023113 DOI: 10.3748/wjg.13.6115] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
429 Demoor PA, Matusov Y, Kelly C, Kolan S, Barnachea L, Bazhenova LA. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer 2011;2:153-64. [PMID: 21475720 DOI: 10.7150/jca.2.153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
430 Gray SW, Armstrong K, Demichele A, Schwartz JS, Hornik RC. Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. Cancer 2009;115:1424-34. [PMID: 19235785 DOI: 10.1002/cncr.24186] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
431 Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging 2017;44:41-54. [PMID: 28396911 DOI: 10.1007/s00259-017-3695-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
432 Zhu Z, Yan L. Next generation of antibody therapy for cancer. Chin J Cancer 2011;30:293-302. [PMID: 21527062 DOI: 10.5732/cjc.011.10123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
433 Sarafan-Vasseur N, Sefrioui D, Tougeron D, Lamy A, Blanchard F, Le Pessot F, Di Fiore F, Michel P, Bézieau S, Latouche JB, Frebourg T, Sesboüé R. Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer. BMC Cancer 2013;13:183. [PMID: 23565769 DOI: 10.1186/1471-2407-13-183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
434 Fiske WH, Threadgill D, Coffey RJ. ERBBs in the gastrointestinal tract: recent progress and new perspectives. Exp Cell Res 2009;315:583-601. [PMID: 19041864 DOI: 10.1016/j.yexcr.2008.10.043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
435 Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 2007;25:773-780. [PMID: 17327601 DOI: 10.1200/jco.2006.07.4187] [Cited by in Crossref: 128] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
436 Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, Ferris RL. Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol 2015;26:40-7. [PMID: 24997207 DOI: 10.1093/annonc/mdu156] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
437 Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389-1400. [PMID: 24202392 DOI: 10.1038/nm.3388] [Cited by in Crossref: 580] [Cited by in F6Publishing: 515] [Article Influence: 72.5] [Reference Citation Analysis]
438 Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: current developments. World J Gastroenterol 2014;20:10425-31. [PMID: 25132758 DOI: 10.3748/wjg.v20.i30.10425] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
439 DeStefanis RA, Kratz JD, Emmerich PB, Deming DA. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep 2019;15:61-9. [PMID: 31130830 DOI: 10.1007/s11888-019-00430-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
440 Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, DE Placido S, Tortora G. Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. Exp Ther Med 2011;2:449-55. [PMID: 22977524 DOI: 10.3892/etm.2011.218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
441 Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011;105:44-52. [PMID: 21629245 DOI: 10.1038/bjc.2011.182] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
442 Voskuil J. How difficult is the validation of clinical biomarkers? F1000Res 2015;4:101. [PMID: 26069732 DOI: 10.12688/f1000research.6395.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
443 Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009;15:6391-6397. [PMID: 19789331 DOI: 10.1158/1078-0432.ccr-09-0877] [Cited by in Crossref: 118] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
444 Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med 2016;8:115. [PMID: 27793177 DOI: 10.1186/s13073-016-0369-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 7.6] [Reference Citation Analysis]
445 Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel S, Maurel J. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol. 2011;32:417-424. [PMID: 21104178 DOI: 10.1007/s13277-010-0136-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
446 Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012;2:74-83. [PMID: 24175199 DOI: 10.5500/wjt.v2.i5.74] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
447 Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs. 2009;27:253-261. [PMID: 19002384 DOI: 10.1007/s10637-008-9182-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
448 Niyazi M, Maihoefer C, Krause M, Rödel C, Budach W, Belka C. Radiotherapy and “new” drugs-new side effects? Radiat Oncol. 2011;6:177. [PMID: 22188921 DOI: 10.1186/1748-717x-6-177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
449 Eng C, Bessudo A, Hart LL, Severtsev A, Gladkov O, Müller L, Kopp MV, Vladimirov V, Langdon R, Kotiv B, Barni S, Hsu C, Bolotin E, von Roemeling R, Schwartz B, Bendell JC. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer 2016;139:177-86. [PMID: 26891420 DOI: 10.1002/ijc.30049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
450 Jin RU, Mills JC. Tumor organoids to study gastroesophageal cancer: a primer. J Mol Cell Biol 2020;12:593-606. [PMID: 32652008 DOI: 10.1093/jmcb/mjaa035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
451 Solomon BJ, Desai J, Rosenthal M, McArthur GA, Pattison ST, Pattison SL, MacDiarmid J, Brahmbhatt H, Scott AM. A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS One 2015;10:e0144559. [PMID: 26659127 DOI: 10.1371/journal.pone.0144559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
452 Loupakis F, Cremolini C, Fontanini G, Stasi I, Salvatore L, Falcone A. Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Ther Adv Med Oncol 2009;1:167-81. [PMID: 21789120 DOI: 10.1177/1758834009348984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
453 Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 2008;27:415-34. [PMID: 18414993 DOI: 10.1007/s10555-008-9143-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
454 Choi YJ, Kim MJ, Lee BH, Kwon MJ, Hwang HS. Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer. Yonsei Med J 2016;57:232-7. [PMID: 26632406 DOI: 10.3349/ymj.2016.57.1.232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
455 Kim H, Hwang H, Lee H, Hong HJ. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. Mol Cells 2017;40:363-70. [PMID: 28535665 DOI: 10.14348/molcells.2017.2282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
456 Lu Y, Li X, Lu H, Fan Z. 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. PLoS One 2010;5:e15823. [PMID: 21209911 DOI: 10.1371/journal.pone.0015823] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
457 Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222-243. [PMID: 20554717 DOI: 10.3322/caac.20075] [Cited by in Crossref: 311] [Cited by in F6Publishing: 250] [Article Influence: 28.3] [Reference Citation Analysis]
458 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015;9:3099-108. [PMID: 26124634 DOI: 10.2147/DDDT.S85567] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
459 Früh M, Pless M. EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice? Transl Lung Cancer Res 2012;1:145-6. [PMID: 25806170 DOI: 10.3978/j.issn.2218-6751.2012.03.01] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
460 Cheng YD, Yang H, Chen GQ, Zhang ZC. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 2013;7:1315-22. [PMID: 24204124 DOI: 10.2147/DDDT.S52485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
461 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, Della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016;22:6345-61. [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
462 Paliogiannis P, Cossu A, Tanda F, Palmieri G, Palomba G. KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett 2014;8:1422-6. [PMID: 25202344 DOI: 10.3892/ol.2014.2411] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
463 Khalifa MA, Rowsell CH, Gladdy R, Ko YJ, Hanna S, Smith A, Law C. Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma? World J Surg Oncol. 2006;4:92. [PMID: 17163999 DOI: 10.1186/1477-7819-4-92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
464 Wu C, Bekaii-Saab T. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract. 2012;2012:359041. [PMID: 22792460 DOI: 10.1155/2012/359041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
465 Nakayama S, Karasawa H, Suzuki T, Yabuuchi S, Takagi K, Aizawa T, Onodera Y, Nakamura Y, Watanabe M, Fujishima F, Yoshida H, Morikawa T, Sase T, Naitoh T, Unno M, Sasano H. p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Med 2017;6:1264-74. [PMID: 28544335 DOI: 10.1002/cam4.1093] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
466 Liu L, Wang E, Li L, Chen D, Peng K, Wang M, Han G. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Can J Gastroenterol Hepatol 2019;2019:2576349. [PMID: 31815114 DOI: 10.1155/2019/2576349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
467 Loree JM, Kopetz S, Raghav KP. Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol 2017;8:199-212. [PMID: 28280626 DOI: 10.21037/jgo.2017.01.01] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
468 Shash E, Peccatori FA, Azim HA Jr. Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). J Thorac Dis 2011;3:57-64. [PMID: 22263061 DOI: 10.3978/j.issn.2072-1439.2010.12.05] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
469 Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S. A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clin Colorectal Cancer 2015;14:154-61. [PMID: 25861837 DOI: 10.1016/j.clcc.2015.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
470 Allard MA, Saffroy R, de la Maisonneuve PB, Ricca L, Bosselut N, Hamelin J, Lecorche E, Bejarano MA, Innominato P, Sebagh M, Adam R, Morère JF, Lemoine A. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? Target Oncol 2015;10:415-21. [PMID: 25420993 DOI: 10.1007/s11523-014-0346-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
471 Tsoulfas G, Pramateftakis MG. Management of rectal cancer and liver metastatic disease: which comes first? Int J Surg Oncol. 2012;2012:196908. [PMID: 22778934 DOI: 10.1155/2012/196908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
472 Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J Neurooncol 2009;95:355-65. [PMID: 19588228 DOI: 10.1007/s11060-009-9945-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
473 Prahallad A, Bernards R. Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene 2016;35:1073-9. [PMID: 25982281 DOI: 10.1038/onc.2015.151] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
474 Rokita M, Stec R, Bodnar L, Charkiewicz R, Korniluk J, Smoter M, Cichowicz M, Chyczewski L, Nikliński J, Kozłowski W, Szczylik C. Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. Onco Targets Ther 2013;6:967-76. [PMID: 23926437 DOI: 10.2147/OTT.S42446] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
475 Johnston SL. Biologic therapies: what and when? J Clin Pathol 2007;60:8-17. [PMID: 17213345 DOI: 10.1136/jcp.2005.032300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
476 Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013;139:367-78. [PMID: 23099994 DOI: 10.1007/s00432-012-1340-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
477 Cathomas G. PIK3CA in Colorectal Cancer. Front Oncol. 2014;4:35. [PMID: 24624362 DOI: 10.3389/fonc.2014.00035] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
478 Kim ES, Mauer AM, William WN Jr, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009;115:1713-22. [PMID: 19208430 DOI: 10.1002/cncr.24148] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
479 Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008;99:1729-34. [PMID: 18827815 DOI: 10.1038/sj.bjc.6604681] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
480 de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 2008;90:89-97. [PMID: 18581057 DOI: 10.1007/s11060-008-9637-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
481 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Reference Citation Analysis]
482 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 326] [Article Influence: 100.0] [Reference Citation Analysis]
483 Groenestege WM, Thébault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260-2267. [PMID: 17671655 DOI: 10.1172/jci31680] [Cited by in Crossref: 243] [Cited by in F6Publishing: 89] [Article Influence: 17.4] [Reference Citation Analysis]
484 Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP, Zhang Y, Liu LZ, Tian L, Guo Y, Sun Y, Ma J. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. BMC Cancer 2018;18:323. [PMID: 29580204 DOI: 10.1186/s12885-018-4268-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
485 Devarakonda CV, Kita D, Phoenix KN, Claffey KP. Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors. BMC Cancer 2015;15:614. [PMID: 26334999 DOI: 10.1186/s12885-015-1608-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
486 Zhuang HQ, Yuan ZY, Wang J, Wang P, Zhao LJ, Zhang BL. Research progress on criteria for discontinuation of EGFR inhibitor therapy. Onco Targets Ther 2012;5:263-70. [PMID: 23082072 DOI: 10.2147/OTT.S36103] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
487 Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol 2014;20:3751-61. [PMID: 24744571 DOI: 10.3748/wjg.v20.i14.3751] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 85] [Article Influence: 16.7] [Reference Citation Analysis]
488 Lordan JT, Riga A, Worthington TR, Karanjia ND. Early and long-term outcomes of patients undergoing liver resection and diaphragm excision for advanced colorectal liver metastases. Ann R Coll Surg Engl 2009;91:483-8. [PMID: 19558763 DOI: 10.1308/003588409x432176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
489 De Luca R, Lo Coco G, Addeo R, Fattoruso SIS, Auriemma A, Paci R, Mistretta O, Epifanio MS, Salvato A, D'Agostino A, Cicero G. Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). World J Oncol 2021;12:104-10. [PMID: 34349854 DOI: 10.14740/wjon1381] [Reference Citation Analysis]
490 Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012;7:e38231. [PMID: 22701615 DOI: 10.1371/journal.pone.0038231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
491 Johnston L, Power M, Sloan P, Long A, Silmon A, Chaffey B, Lisgo AJ, Little L, Vercauteren E, Steiniche T, Meyer T, Simpson J. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. J Clin Pathol 2018;71:336-43. [PMID: 28899979 DOI: 10.1136/jclinpath-2017-204629] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
492 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
493 Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005;28:417-33. [PMID: 15853443 DOI: 10.2165/00002018-200528050-00005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
494 Amadio A, Burkes R, Bailie T, McLean M, Coleman B. Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients. Curr Oncol 2014;21:e52-61. [PMID: 24523621 DOI: 10.3747/co.21.1645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
495 Kim JE, Kim KK, Kim SY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. J Cancer 2017;8:2263-8. [PMID: 28819429 DOI: 10.7150/jca.19582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
496 Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, Feng HP, Shimamoto T, Noguchi K, Ohtsu A. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2013;72:643-52. [PMID: 23921573 DOI: 10.1007/s00280-013-2240-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
497 Verdaguer H, Saurí T, Macarulla T. Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. J Gastrointest Oncol 2017;8:405-17. [PMID: 28736628 DOI: 10.21037/jgo.2016.11.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
498 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
499 Shiovitz S, Grady WM. Molecular markers predictive of chemotherapy response in colorectal cancer. Curr Gastroenterol Rep 2015;17:431. [PMID: 25663616 DOI: 10.1007/s11894-015-0431-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
500 Brijwani N, Jain M, Dhandapani M, Zahed F, Mukhopadhyay P, Biswas M, Khatri D, Radhakrishna VD, Majumder B, Radhakrishnan P, Thiyagarajan S. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Sci Rep 2017;7:1502. [PMID: 28473715 DOI: 10.1038/s41598-017-01566-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
501 Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20:4208-19. [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
502 Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer 2017;64. [PMID: 28544128 DOI: 10.1002/pbc.26621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
503 Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-3610. [PMID: 20606093 DOI: 10.1200/jco.2009.25.7550] [Cited by in Crossref: 425] [Cited by in F6Publishing: 237] [Article Influence: 38.6] [Reference Citation Analysis]
504 Andreuzzi E, Capuano A, Poletto E, Pivetta E, Fejza A, Favero A, Doliana R, Cannizzaro R, Spessotto P, Mongiat M. Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis. Int J Mol Sci 2020;21:E3686. [PMID: 32456248 DOI: 10.3390/ijms21103686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
505 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
506 Krishnamurthi SS, Seo Y, Kinsella TJ. Adjuvant therapy for rectal cancer. Clin Colon Rectal Surg 2007;20:167-81. [PMID: 20011198 DOI: 10.1055/s-2007-984861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
507 Xu W, Yang Z, Lu N. Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res. 2016;35:1. [PMID: 26728266 DOI: 10.1186/s13046-015-0276-9] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
508 Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. World J Gastroenterol. 2014;20:14018-14032. [PMID: 25320542 DOI: 10.3748/wjg.v20.i38.14018] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
509 Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab 2013;98:1333-42. [PMID: 23450053 DOI: 10.1210/jc.2012-4085] [Cited by in Crossref: 52] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
510 Post JB, Hami N, Mertens AEE, Elfrink S, Bos JL, Snippert HJG. CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition. Oncotarget. 2019;10:1440-1457. [PMID: 30858928 DOI: 10.18632/oncotarget.26677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
511 Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009;19:63-8. [PMID: 19028347 DOI: 10.1016/j.semradonc.2008.09.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
512 Hu T, Li Z, Gao CY, Cho CH. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 2016;22:6876-6889. [PMID: 27570424 DOI: 10.3748/wjg.v22.i30.6876] [Cited by in CrossRef: 133] [Cited by in F6Publishing: 125] [Article Influence: 33.3] [Reference Citation Analysis]
513 Silkin SV, Startsev SS, Krasnova ME, Raskin GA, Mitiushkina NV, Iyevleva AG, Sokolenko AP, Imyanitov EN. Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan. J Gastrointest Cancer 2016;47:502-5. [PMID: 26687137 DOI: 10.1007/s12029-015-9792-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
514 Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys 2016;95:1346-54. [PMID: 27212198 DOI: 10.1016/j.ijrobp.2016.03.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
515 Okita K, Hara Y, Okura H, Hayashi H, Sasaki Y, Masuko S, Kitadai E, Masuko K, Yoshimoto S, Hayashi N, Sugiura R, Endo Y, Okazaki S, Arai S, Yoshioka T, Matsumoto T, Makino Y, Komiyama H, Sakamoto K, Masuko T. Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene. Cancer Sci 2021;112:563-74. [PMID: 33211385 DOI: 10.1111/cas.14741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
516 Liu Y, Ramírez J, House L, Ratain MJ. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer 2010;46:2097-103. [PMID: 20580994 DOI: 10.1016/j.ejca.2010.04.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
517 Jeantet M, Tougeron D, Tachon G, Cortes U, Archambaut C, Fromont G, Karayan-Tapon L. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. Int J Mol Sci 2016;17:E2015. [PMID: 27916952 DOI: 10.3390/ijms17122015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
518 Akita S, Hattori N, Masuda T, Horimasu Y, Nakashima T, Iwamoto H, Fujitaka K, Miyake M, Kohno N. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model. Cancer Sci 2015;106:921-8. [PMID: 25950387 DOI: 10.1111/cas.12692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
519 Lungulescu CV, Ungureanu BS, Turcu-Stiolica A, Ghimpau V, Artene SA, Cazacu IM, Grecu AF, Dinescu VC, Croitoru A, Volovat SR. The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. Sci Rep 2020;10:21355. [PMID: 33288791 DOI: 10.1038/s41598-020-78497-7] [Reference Citation Analysis]
520 Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol. 2013;18:670-677. [PMID: 22638623 DOI: 10.1007/s10147-012-0422-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
521 Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathol Oncol Res. 2017;23:673-677. [PMID: 28025786 DOI: 10.1007/s12253-016-0166-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
522 Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, Farinotti R, Bonhomme-Faivre L. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol 2010;27:1066-72. [PMID: 19862647 DOI: 10.1007/s12032-009-9336-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
523 Moreno-Gonzalez A, Olson JM, Klinghoffer RA. Predicting responses to chemotherapy in the context that matters - the patient. Mol Cell Oncol 2016;3:e1057315. [PMID: 27308571 DOI: 10.1080/23723556.2015.1057315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
524 Bermúdez M, Aguilar-Medina M, Lizárraga-Verdugo E, Avendaño-Félix M, Silva-Benítez E, López-Camarillo C, Ramos-Payán R. LncRNAs as Regulators of Autophagy and Drug Resistance in Colorectal Cancer. Front Oncol 2019;9:1008. [PMID: 31632922 DOI: 10.3389/fonc.2019.01008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
525 Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 2014;16 Suppl 8:viii7-13. [PMID: 25342602 DOI: 10.1093/neuonc/nou232] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
526 Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, Yamamoto M, Hayashi K. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer 2012;12:88. [PMID: 22409860 DOI: 10.1186/1471-2407-12-88] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
527 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:106-115. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558] [Reference Citation Analysis]
528 Cruickshanks N. When to screen and not to screen. Cancer Biol Ther 2014;15:147-8. [PMID: 24424112 DOI: 10.4161/cbt.27741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
529 Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open 2018;3:e000375. [PMID: 29942666 DOI: 10.1136/esmoopen-2018-000375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
530 Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H, Ding Q, Xia J. Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis. J Biol Chem 2016;291:21085-95. [PMID: 27432879 DOI: 10.1074/jbc.M116.717892] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
531 Ozeki K, Tanida S, Morimoto C, Inoue Y, Mizoshita T, Tsukamoto H, Shimura T, Kataoka H, Kamiya T, Nishiwaki E, Ishiguro H, Higashiyama S, Joh T. Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One. 2013;8:e56770. [PMID: 23451083 DOI: 10.1371/journal.pone.0056770] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
532 Lewis AL, Holden RR, Chung ST, Czuczman P, Kuchel T, Finnie J, Porter S, Foster D. Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. J Mater Sci Mater Med 2013;24:115-27. [PMID: 23015264 DOI: 10.1007/s10856-012-4768-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
533 Azer SA, Azer S. Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open 2016;6:e009889. [PMID: 26857105 DOI: 10.1136/bmjopen-2015-009889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
534 Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-8. [PMID: 16450000 DOI: 10.1038/sj.bjc.6602963] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 4.8] [Reference Citation Analysis]
535 Liu J, Hu J, Cheng L, Ren W, Yang M, Liu B, Xie L, Qian X. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. Onco Targets Ther 2016;9:557-65. [PMID: 26869800 DOI: 10.2147/OTT.S86966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
536 Yashiro M, Qiu H, Hasegawa T, Zhang X, Matsuzaki T, Hirakawa K. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. Br J Cancer. 2011;105:1522-1532. [PMID: 21997136 DOI: 10.1038/bjc.2011.397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
537 Hasbal-Celikok G, Aksoy-Sagirli P, Altiparmak-Ulbegi G, Can A. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. Oncol Lett 2021;21:209. [PMID: 33574948 DOI: 10.3892/ol.2021.12470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324-331. [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770] [Cited by in Crossref: 156] [Cited by in F6Publishing: 122] [Article Influence: 14.2] [Reference Citation Analysis]
539 Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19:619-625. [PMID: 23584089 DOI: 10.1038/nm.3175] [Cited by in Crossref: 597] [Cited by in F6Publishing: 511] [Article Influence: 74.6] [Reference Citation Analysis]
540 Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012;2012:406830. [PMID: 22675625 DOI: 10.1155/2012/406830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
541 Terragni R, Casadei Gardini A, Sabattini S, Bettini G, Amadori D, Talamonti C, Vignoli M, Capelli L, Saunders JH, Ricci M, Ulivi P. EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model? PLoS One 2014;9:e85388. [PMID: 24454858 DOI: 10.1371/journal.pone.0085388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
542 Wang X, Fang H, Cheng Y, Li L, Sun X, Fu T, Huang P, Zhang A, Feng Z, Li C, Huang X, Li G, Du P, Yang H, Fang X, Li F, Gao Q, Liu B. The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. Carcinogenesis 2018;39:708-18. [DOI: 10.1093/carcin/bgy040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
543 Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH. Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget 2015;6:7262-79. [PMID: 25788261 DOI: 10.18632/oncotarget.3225] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
544 Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, Serafico A, Villa E. Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. J Oncol 2009;2009:849051. [PMID: 19584908 DOI: 10.1155/2009/849051] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
545 Petrilli R, Eloy JO, Lopez RF, Lee RJ. Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells. Anticancer Agents Med Chem 2017;17:301-8. [PMID: 27225449 DOI: 10.2174/1871520616666160526110913] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
546 Liu N, Wu C, Jia R, Cai G, Wang Y, Zhou L, Ji Q, Sui H, Zeng P, Xiao H, Liu H, Huo J, Feng Y, Deng W, Li Q. Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Front Pharmacol 2020;11:478. [PMID: 32372960 DOI: 10.3389/fphar.2020.00478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
547 Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol 2015;76:1113-32. [PMID: 26391154 DOI: 10.1007/s00280-015-2861-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 10.5] [Reference Citation Analysis]
548 Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother Pharmacol. 2014;73:749-757. [PMID: 24500024 DOI: 10.1007/s00280-014-2401-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
549 Okugawa Y, Toiyama Y, Goel A. An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn. 2014;14:999-1021. [PMID: 25163355 DOI: 10.1586/14737159.2014.946907] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
550 Tural D, Batur S, Erdamar S, Akar E, Kepil N, Mandel NM, Serdengeçti S. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumour Biol. 2014;35:1041-1049. [PMID: 23996432 DOI: 10.1007/s13277-013-1138-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
551 Morris ZS, Harari PM. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 2014;32:2886-93. [PMID: 25113770 DOI: 10.1200/JCO.2014.55.1366] [Cited by in Crossref: 63] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
552 Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget 2016;7:8399-412. [PMID: 26716414 DOI: 10.18632/oncotarget.6724] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
553 Zhou Y, Zou H, Zhang S, Marks JD. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol 2010;404:88-99. [PMID: 20851130 DOI: 10.1016/j.jmb.2010.09.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
554 Chen Y, Cao D, Bi F, Li Q, Qiu M. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. Med Oncol 2014;31:935. [PMID: 24683007 DOI: 10.1007/s12032-014-0935-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
555 Cortez-Jugo C, Qi A, Rajapaksa A, Friend JR, Yeo LY. Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics 2015;9:052603. [PMID: 25945147 DOI: 10.1063/1.4917181] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
556 Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Pierantoni C, Cascinu S. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer 2007;97:92-7. [PMID: 17579627 DOI: 10.1038/sj.bjc.6603847] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
557 Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 2015;34:531-536. [PMID: 24469059 DOI: 10.1038/onc.2013.588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
558 Dascalu B, Kennecke HF, Lim HJ, Renouf DJ, Ruan JY, Chang JT, Cheung WY. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Support Care Cancer 2016;24:799-805. [PMID: 26184500 DOI: 10.1007/s00520-015-2846-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
559 Martin SZ, Wagner DC, Hörner N, Horst D, Lang H, Tagscherer KE, Roth W. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer 2019;19:1030. [PMID: 31675944 DOI: 10.1186/s12885-019-6270-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
560 Kyriakou F, Kountourakis P, Papamichael D. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Target Oncol 2011;6:245-51. [PMID: 22068891 DOI: 10.1007/s11523-011-0198-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
561 Mariotte D, Dupont B, Gervais R, Galais MP, Laroche D, Tranchant A, Comby E, Bouhier-Leporrier K, Reimund JM, Le Mauff B. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 2011;3:396-401. [PMID: 21654207 DOI: 10.4161/mabs.3.4.16293] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
562 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
563 Nagaraju GP, Alese OB, Landry J, Diaz R, El-Rayes BF. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget 2014;5:9980-91. [PMID: 25296971 DOI: 10.18632/oncotarget.2484] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
564 Lorusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs 2011;29:1395-405. [PMID: 20607586 DOI: 10.1007/s10637-010-9484-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
565 Yang HT, Shah RH, Tegay D, Onel K. Precision oncology: lessons learned and challenges for the future. Cancer Manag Res 2019;11:7525-36. [PMID: 31616176 DOI: 10.2147/CMAR.S201326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
566 Khan SA, Matthews JB. Intraoperative margin re-resection for colorectal cancer liver metastases. Hepatobiliary Surg Nutr 2013;2:108-12. [PMID: 24570924 DOI: 10.3978/j.issn.2304-3881.2012.10.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
567 de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG, Lacal JC. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One. 2013;8:e64961. [PMID: 23762272 DOI: 10.1371/journal.pone.0064961] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
568 El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget 2016;7:73618-37. [PMID: 27655662 DOI: 10.18632/oncotarget.12037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
569 Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011;16:1729-40. [PMID: 22135123 DOI: 10.1634/theoncologist.2011-0163] [Cited by in Crossref: 90] [Cited by in F6Publishing: 74] [Article Influence: 9.0] [Reference Citation Analysis]
570 Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Allen PJ, Fong YC, Cercek A, D'Angelica MI. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113:477-484. [PMID: 26830685 DOI: 10.1002/jso.24189] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
571 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 537] [Cited by in F6Publishing: 448] [Article Influence: 76.7] [Reference Citation Analysis]
572 Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark E. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol. 2011;127:1286-93.e6. [PMID: 21453959 DOI: 10.1016/j.jaci.2011.02.019] [Cited by in Crossref: 337] [Cited by in F6Publishing: 265] [Article Influence: 33.7] [Reference Citation Analysis]
573 Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Martínez-Cardús A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol 2013;30:428. [PMID: 23338968 DOI: 10.1007/s12032-012-0428-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
574 Khemtong C, Kessinger CW, Gao J. Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb) 2009;:3497-510. [PMID: 19521593 DOI: 10.1039/b821865j] [Cited by in Crossref: 138] [Cited by in F6Publishing: 114] [Article Influence: 11.5] [Reference Citation Analysis]
575 Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers (Basel) 2019;11:E1321. [PMID: 31500168 DOI: 10.3390/cancers11091321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
576 Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, Urso CE, Wang Y, Ramos C, Steadman K, Pishvaian MJ. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer. 2015;121:1645-1653. [PMID: 25641763 DOI: 10.1002/cncr.29224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
577 Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010;119:451-6. [PMID: 20837357 DOI: 10.1016/j.ygyno.2010.08.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
578 Steele N, Anthony A, Saunders M, Esmarck B, Ehrnrooth E, Kristjansen PE, Nihlén A, Hansen LT, Cassidy J. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer 2012;106:793-8. [PMID: 22315057 DOI: 10.1038/bjc.2011.599] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
579 Wang Q, Wei F, Li C, Lv G, Wang G, Liu T, Bellail AC, Hao C. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PLoS One 2013;8:e73175. [PMID: 23991179 DOI: 10.1371/journal.pone.0073175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
580 Hirschi B, Gallmeier E, Ziesch A, Marschall M, Kolligs FT. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. Mol Cancer 2014;13:122. [PMID: 24885690 DOI: 10.1186/1476-4598-13-122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
581 Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S18-30. [PMID: 20680104 DOI: 10.3747/co.v17is1.615] [Cited by in Crossref: 11] [Cited by in F6Publishing: 35] [Article Influence: 1.1] [Reference Citation Analysis]
582 Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic Metastasis from Colorectal Cancer. Euroasian J Hepatogastroenterol 2017;7:166-75. [PMID: 29201802 DOI: 10.5005/jp-journals-10018-1241] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
583 Luu C, Arrington AK, Schoellhammer HF, Singh G, Kim J. Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol 2013;4:328-36. [PMID: 23997944 DOI: 10.3978/j.issn.2078-6891.2013.032] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
584 Wang L, Chen YZ, Shi D, Shi XY, Zou Z, Zhao JH. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis. Drugs R D 2011;11:317-26. [PMID: 22133387 DOI: 10.2165/11598190-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
585 Nguyen HL, Hwang J. Treatment of metastatic colorectal cancer in the elderly. Curr Treat Options Oncol 2009;10:287-95. [PMID: 19821033 DOI: 10.1007/s11864-009-0111-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
586 Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, Blanke CD. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 2010;5:1472-6. [PMID: 20631636 DOI: 10.1097/JTO.0b013e3181e77a92] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
587 Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 2008;10:35-46. [PMID: 18208791 DOI: 10.1007/s12094-008-0150-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
588 Granito A, Marinelli S, Negrini G, Menetti S, Benevento F, Bolondi L. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol 2016;9:240-9. [PMID: 26929785 DOI: 10.1177/1756283X15618129] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 8.6] [Reference Citation Analysis]
589 Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlücker E, Meyer-Pittroff R, Ott OJ, Fietkau R, Gaipl US, Frey B. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol 2012;2:132. [PMID: 23087898 DOI: 10.3389/fonc.2012.00132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
590 Liang J, E M, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, Chen D, Zou S, Lu N, Perez-Rodríguez R, Zheng J, Wang L. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. Onco Targets Ther 2013;6:1589-96. [PMID: 24235844 DOI: 10.2147/OTT.S50945] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
591 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Schimanski CC, Staib F, Göhler T, Hebart H, Heike M, Neise M, Rudi J, Geer T, Dingeldein G, Lang C, Ehscheidt P, Flohr T, Josten KM, Karthaus M, Schmittel A, Wierecky J, Boller E, Indorf M, Wörns MA, Galle PR, Moehler M. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. J Cancer Res Clin Oncol 2017;143:1023-34. [PMID: 28197787 DOI: 10.1007/s00432-017-2344-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
593 Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 2011;14:219-225. [PMID: 21409520 DOI: 10.1007/s10120-011-0031-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
594 Lièvre A, Laurent-Puig P. Genetics: Predictive value of KRAS mutations in chemoresistant CRC. Nat Rev Clin Oncol 2009;6:306-7. [PMID: 19483733 DOI: 10.1038/nrclinonc.2009.69] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
595 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
596 Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, Lee J, Park YS, Sun JM, Kim HJ, Kim CK, Yi SY, Jang JS, Park K, Kim HJ. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Support Care Cancer 2016;24:301-9. [PMID: 26041481 DOI: 10.1007/s00520-015-2783-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
597 Georgakopoulou E, Scully C. Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J 2015;218:671-7. [PMID: 26114697 DOI: 10.1038/sj.bdj.2015.439] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
598 Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 2016;5:2249-60. [PMID: 27465221 DOI: 10.1002/cam4.806] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
599 Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol 2016;7:340-51. [PMID: 27777877 DOI: 10.5306/wjco.v7.i5.340] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
600 Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 2014;1:540-9. [PMID: 25594061 DOI: 10.18632/oncoscience.73] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
601 Hassan AB, Paraskeva C. Colorectal cancer prognosis: is it all mutation, mutation, mutation? Gut 2005;54:1209-11. [PMID: 16099785 DOI: 10.1136/gut.2005.070946] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
602 Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist. 2016;21:1483-1491. [PMID: 27449521 DOI: 10.1634/theoncologist.2016-0051] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
603 Zervoudakis A, Boucher T, Kemeny NE. Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion. Visc Med 2017;33:47-53. [PMID: 28612017 DOI: 10.1159/000454693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
604 Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther 2011;12:436-46. [PMID: 21725209 DOI: 10.4161/cbt.12.5.16394] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
605 Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology. 2015;149:1204-1225.e12. [PMID: 26216839 DOI: 10.1053/j.gastro.2015.07.011] [Cited by in Crossref: 317] [Cited by in F6Publishing: 294] [Article Influence: 52.8] [Reference Citation Analysis]
606 Prince AC, Jani A, Korb M, Tipirneni KE, Kasten BB, Rosenthal EL, Warram JM. Characterizing the detection threshold for optical imaging in surgical oncology. J Surg Oncol 2017;116:898-906. [PMID: 28628728 DOI: 10.1002/jso.24733] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
607 Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH, Wang X, Tang I, Zheng E, Qiu W, Wainberg ZA, Nel AE, Meng H. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer. ACS Nano 2019;13:38-53. [PMID: 30525443 DOI: 10.1021/acsnano.8b06164] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
608 Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 2018;17:85-96. [PMID: 29576427 DOI: 10.1016/j.clcc.2017.12.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
609 Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018;17:48. [PMID: 29455673 DOI: 10.1186/s12943-018-0804-2] [Cited by in Crossref: 331] [Cited by in F6Publishing: 249] [Article Influence: 110.3] [Reference Citation Analysis]
610 Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem. 2009;284:10912-10922. [PMID: 19224914 DOI: 10.1074/jbc.m809551200] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
611 Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncol 2019;91:69-78. [PMID: 30926065 DOI: 10.1016/j.oraloncology.2019.02.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
612 Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010;9:843-56. [PMID: 21031001 DOI: 10.1038/nrd3216] [Cited by in Crossref: 168] [Cited by in F6Publishing: 142] [Article Influence: 15.3] [Reference Citation Analysis]
613 Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93:510-514. [PMID: 16091760 DOI: 10.1038/sj.bjc.6602733] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
614 Kanwar SS, Nautiyal J, Majumdar AP. EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new? Curr Drug Targets 2010;11:682-98. [PMID: 20298154 DOI: 10.2174/138945010791170851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
615 Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ. Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer. 2013;108:771-774. [PMID: 23412099 DOI: 10.1038/bjc.2013.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
616 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-327. [PMID: 20414205 DOI: 10.1038/nri2744] [Cited by in Crossref: 773] [Cited by in F6Publishing: 858] [Article Influence: 70.3] [Reference Citation Analysis]
617 Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16:16-26. [PMID: 19229368 DOI: 10.3747/co.v16i1.361] [Cited by in Crossref: 85] [Cited by in F6Publishing: 60] [Article Influence: 7.7] [Reference Citation Analysis]
618 Balachandran VP, Arora A, Gönen M, Ito H, Turcotte S, Shia J, Viale A, Snoeren N, van Hooff SR, Rinkes IH, Adam R, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clin Cancer Res 2016;22:2575-82. [PMID: 26733613 DOI: 10.1158/1078-0432.CCR-15-1071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
619 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
620 Burotto M, Hartley ML, Marshall JL, Pishvaian MJ. Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 2012;1. [PMID: 24273599 DOI: 10.2217/crc.12.52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
621 Yang SH, Hong YK, Jeun SS, Kim IS, Hong JT, Sung JH, Son BC, Lee SW, Kim MC, Lee KS. Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse. J Neurooncol 2009;95:23-8. [PMID: 19381443 DOI: 10.1007/s11060-009-9895-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
622 Stoll SW, Stuart PE, Lambert S, Gandarillas A, Rittié L, Johnston A, Elder JT. Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation. J Invest Dermatol 2016;136:444-52. [PMID: 26802239 DOI: 10.1016/j.jid.2015.10.061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
623 Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500-1508. [PMID: 25225906 DOI: 10.1038/bjc.2014.419] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
624 Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16:228-238. [PMID: 21273511 DOI: 10.1634/theoncologist.2010-0298] [Cited by in Crossref: 73] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
625 Chan HT, Chin YM, Low SK. The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncol Ther 2019;7:1-32. [PMID: 32700193 DOI: 10.1007/s40487-018-0090-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
626 Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galisia E, Giustini L, Silva RR, Bisonni R. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist. 2011;16:53-60. [PMID: 21212430 DOI: 10.1634/theoncologist.2010-0119] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
627 Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, Mitter R, Primrose JN, Thomas GJ, Packham GK. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis. 2013;4:e684. [PMID: 23788041 DOI: 10.1038/cddis.2013.213] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
628 Kennecke H, Chen L, Blanke CD, Cheung WY, Schaff K, Speers C. Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer. Curr Oncol 2013;20:326-32. [PMID: 24311948 DOI: 10.3747/co.20.1600] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
629 Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol. 2016;22:6362-6372. [PMID: 27605872 DOI: 10.3748/wjg.v22.i28.6362] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
630 Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48. [PMID: 26184520 DOI: 10.1016/S1470-2045(15)00138-2] [Cited by in Crossref: 209] [Cited by in F6Publishing: 114] [Article Influence: 34.8] [Reference Citation Analysis]
631 Zhang M, Huang H, Li X, Huang Y, Chen C, Fang X, Wang Z, Guo C, Lam S, Fu X, Hong H, Tian Y, Lu T, Lin T. Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen. Front Oncol 2020;10:1011. [PMID: 32637360 DOI: 10.3389/fonc.2020.01011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
632 Shankaran V, Wisinski KB, Mulcahy MF, Benson AB 3rd. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 2008;12:87-98. [PMID: 18422373 DOI: 10.1007/BF03256274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
633 Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R. Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect 2009;85:261-3. [PMID: 19625295 DOI: 10.1136/sti.2008.034959] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
634 Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743-750. [PMID: 24782321 DOI: 10.1101/gr.165985.113] [Cited by in Crossref: 399] [Cited by in F6Publishing: 357] [Article Influence: 57.0] [Reference Citation Analysis]
635 Mei Z, Shao YW, Lin P, Cai X, Wang B, Ding Y, Ma X, Wu X, Xia Y, Zhu D, Shu Y, Fu Z, Gu Y. SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients. BMC Cancer. 2018;18:479. [PMID: 29703253 DOI: 10.1186/s12885-018-4298-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
636 Herreros-Villanueva M, Rodrigo M, Claver M, Muñiz P, Lastra E, García-Girón C, Coma del Corral MJ. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011;38:1315-20. [PMID: 20563851 DOI: 10.1007/s11033-010-0232-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
637 Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69:58-66. [PMID: 20078613 DOI: 10.1111/j.1365-2125.2009.03556.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
638 Tao X, Lu Y, Qiu S, Wang Y, Qin J, Fan Z. AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. Cancer Lett 2017;408:33-42. [PMID: 28823958 DOI: 10.1016/j.canlet.2017.08.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
639 Shida D, Fang X, Kordula T, Takabe K, Lépine S, Alvarez SE, Milstien S, Spiegel S. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008;68:6569-6577. [PMID: 18701480 DOI: 10.1158/0008-5472.can-08-0411] [Cited by in Crossref: 100] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
640 Hong CS, Sun EG, Choi JN, Kim DH, Kim JH, Ryu KH, Shim HJ, Hwang JE, Bae WK, Kim HR, Kim KK, Jung C, Chung IJ, Cho SH. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. Cancer Sci 2020;111:3268-78. [PMID: 32533590 DOI: 10.1111/cas.14526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
641 Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract 2014;2014:734249. [PMID: 24723942 DOI: 10.1155/2014/734249] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
642 Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Fujii H. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 2010;102:520-9. [PMID: 20029417 DOI: 10.1038/sj.bjc.6605502] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
643 Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011;29:366-73. [PMID: 19997960 DOI: 10.1007/s10637-009-9363-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
644 Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer 2007;97:857-61. [PMID: 17876336 DOI: 10.1038/sj.bjc.6603942] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
645 Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J Exp Clin Cancer Res 2017;36:89. [PMID: 28659146 DOI: 10.1186/s13046-017-0558-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
646 Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011;16:452-463. [PMID: 21786210 DOI: 10.1007/s10147-011-0291-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
647 Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget 2016;7:53668-78. [PMID: 27449091 DOI: 10.18632/oncotarget.10696] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
648 Sahoo D. The power of boolean implication networks. Front Physiol 2012;3:276. [PMID: 22934030 DOI: 10.3389/fphys.2012.00276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Art